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Abstract
ELABORATION AND DESIGN OF α7 nAChR NEGATIVE ALLOSTERIC MODULATORS

By Osama Ibrahim Alwassil, Ph.D.
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2015
Major Director: Małgorzata Dukat, Associate Professor, Department of Medicinal Chemistry
α7 Neuronal nicotinic acetylcholine receptors are one of two major classes of receptors
responsible for cholinergic neurotransmission in the central nervous system. The existence of α7
neuronal nAChRs in different regions of the nervous system suggests their involvement in
certain essential physiological functions as well as in disorders such as Alzheimer’s disease
(AD), drug dependence, and depression. This project was aimed toward the discovery and
development of small–molecule arylguanidines that modulate α7 nAChR function with improved
subtype-selectivity through an allosteric approach. Identifying the required structural features of
these small molecules allowed optimization of their negative allosteric modulator (NAM) actions
at α7 neuronal nAChRs. MD-354 (3-chlorophenylguanidine) was the first small–molecule NAM
at α7 nAChRs; however, it also binds at 5-HT3 receptors. The N-methyl analog of MD-354
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appeared to be more selective toward α7 nAChRs than 5-HT3 receptors. Comparative studies
using two series of novel compounds based on MD-354 and its N-methyl analog explored the
aryl 3-position and investigated whether or not the MD-354 series and the N-methyl series bind
in the same manner. Biological potencies of the MD-354 series and the N-methyl series of
compounds, obtained from electrophysiological assays with Xenopus laevis oocytes expressing
human α7 nAChRs in two-electrode voltage-clamp assays, showed that N-(3-iodophenyl)-Nmethylguanidine (28) is the most potent analog at α7 nAChRs. Our comparative study and
Hansch analyses indicated different binding modes of the two series.
In addition, we investigated: i) the length/size of the aliphatic side chain at the anilinic
nitrogen, ii) the effect of alkylating the guanidine nitrogen atoms, and iii) the necessity of the
presence of these nitrogen atoms for the inhibitory effects of arylguanidines at α7 nAChRs.
In efforts to explain the varied functional activity of these arylguanidines, homology models
of the extracellular domain and the transmembrane domain of human α7 nAChRs were
developed, allosteric sites identified, and docking studies and hydropathic analysis conducted.
The 3D quantitative structure-activity relationships for our compounds were also analyzed using
CoMFA. A pharmacophore for arylguanidines as α7 nAChR NAMs was identified.
Together, these data should be useful for the subsequent design of novel arylguanidine
analogs for their potential treatment of neurological disorders.
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I. Introduction

In the human body, neurotransmitter receptors play a central role in cellular
communication within various kinds of organs and tissues. They are vital proteins with a
wide range of recognition capacity allowing them to process precise signal transduction,
specifically in neurons. The localization and density of all neurotransmitter receptors on
neuronal cells in the central nervous system (CNS) and the peripheral nervous system
(PNS) are highly regulated.1,2 Generally, there are numerous types of receptors and,
among them, only one superfamily of receptors, the ligand-gated ion channel (LGIC)
superfamily, exhibits a significantly rapid role in the processing of chemical-to-electrical
transduction during neuronal signaling.2 Cholinergic neurons are characterized by the
storage, release, and stimulation of the neurotransmitter acetylcholine (ACh) in the CNS
and PNS.2 At intercellular connections (i.e., synapses), the release of ACh from
presynaptic neurons into the synaptic cleft initiates channel opening of nicotinic
acetylcholine receptors (nAChRs), one of the most widely studied families of the LGIC
receptors, in the postsynaptic region. This initiation of the open channel leads to the
transfer of ions across the cell membrane and to depolarization at the motor endplate and
subsequent stimulation of the targeted tissue. The family of nAChRs are part of the Cys-
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loop family of receptors, which were named because of the presence of a well-known
disulfide bridge in their N-terminal domain within the superfamily of LGIC receptors.
Neuronal nAChRs are the center of many extensive scientific investigations because
of their involvement in numerous important neurophysiological pathways such as
cognitive learning and memory, synaptic plasticity, and neuroprotection.3,4 In addition,
nAChRs exist in discrete locations and are involved in distinct processes such as arousal,
cerebral blood flow and metabolism, and inflammation. Also, nAChRs can be located
presynaptically for the regulation of neurotransmitter release, and both pre- and
postsynaptic nAChR expression is altered by numerous pathophysiological disorders.
Among these disorders are two critical worldwide health problems of current interest that
are believed to be mediated through nAChRs: i) dementia and ii) certain aspects of drug
abuse. At the molecular level, however, there is little information about these receptors,
and their gating mechanism (i.e., ligand affinity and selectivity, dynamics of channel
activation/inactivation, ion specificity and conductance, and desensitization properties) is
still poorly understood.
i) Alzheimer’s disease (AD) is one of the most costly neuropsychiatric disorders,
even when compared to other diseases such as stroke and heart disease. AD is a common
form of dementia estimated to cause in all ages 5.3 million cases in 2015 in the US.5
Among those, approximately 5.1 million Americans are age of 65 or older, and around
200,000 Americans experienced early onset AD (i.e., under age 65). It is also estimated
that an additional 3.5 million health care personnel will be needed by 2030 to preserve
the present ratio of health care personnel to elderly Americans.5 Consequently, health
care, extended term care and clinical expenses, are anticipated to drastically rise from
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$203 billion in 2013 to an estimated $1.2 trillion by the year 2050.5 The available current
therapies on the market are associated with severe side effects and do not effectively
cover the problem of disease progression or improving patients’ quality of life.5 An
optimal treatment should provide sufficient effectiveness to halt the progression of AD
symptoms or even reverse the phases of this disease.
ii) Drug of abuse (specifically marijuana abuse) is a problem that is estimated to
cause around 1,243,000 cases seeking treatment per year in the United States.6,7 This
number is more than the number of patients looking for treatment for cocaine or heroin
use.6
There are indications that agents that can antagonize the effects of ACh are of
therapeutic value. There are two types of such agents: i) direct-acting antagonists (i.e.,
those that block the effect of ACh at orthosteric binding site), and ii) indirect-acting
antagonists (i.e., those that act via an allosteric mechanism, such as negative allosteric
modulators). Arylguanidines were identified in our laboratory as the first novel class of
small–molecule negative allosteric modulators (NAMs) of α7 nAChRs (e.g., mchlorophenylguanidine mCPG; MD-354; IC50 = 7.98 µM).8 Because of a selectivity
problem associated with MD-354 (i.e., it also binds at 5-HT3 receptor), we previously
investigated arylguanidine structural components that are required for α7 nAChRs and
that detract from 5-HT3 receptor binding.9 Here, we continue our previous investigation
by examining different structural aspects of arylguanidines that are required for α7
nAChR action using various medicinal chemistry approaches in order to develop novel
analogs with an improved selectivity and inhibitory potency for α7 nAChRs.

!

3!

!

As a powerful tool in medicinal chemistry, molecular modeling has proven to provide
significant molecular insight into various bimolecular interactions. It would be instructive
to examine the possible interaction site(s) and mechanisms by which small-molecule α7
nAChR NAMs work. Since a crystal structure of the human α7 nACh receptor has not yet
been determined, three-dimensional models of the extracellular domain (ECD) and the
transmembrane domain (TMD) of human α7 nAChRs will be constructed in this work
based on available nAChR crystal structures from different species. The results should
allow, with certain caveats, for detailed insight about α7 nAChR allosteric sites and
enhance the effort to develop novel small–molecule NAMs.
The present investigation is aimed at understanding why and how arylguanidines
work as NAMs of ACh action at α7 nACh receptors.
!
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II. Background

A. Cholinergic Receptors

In the CNS, cholinergic neuronal networks might represent the most important
neuromodulatory neurotransmitter system.2,10 This cholinergic system is widely
distributed and exists in both projection neurons and interneurons.11,12 The primary
function of these neurons is to control activities that depend on selective attention, and to
regulate higher cognitive functions such as memory and learning.2 Two major pathways
that are considered the sources of the cholinergic system are the basal-forebrain
cholinergic neurons and the pedunculopontine–lateral dorsal tegmental neurons where
they project by widespread innervation to almost every area of the brain (Figure 1).13,14 In
addition, cholinergic interneurons exist in multiple brain regions such as the striatum and
neocortex where they provide innervation for nearby neurons.15,16 Both types of
cholinergic neurons originate from the laterodorsal tegmental nucleus (LDT) or
pedunculopontine tegmental nucleus (PPT), and cholinergic interneurons in the striatum
regulate the mesolimbic dopamine system through acetylcholine receptors (AChRs)
expressed on multiple neuronal populations within the system (e.g., dopaminergic
neurons).15,16
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Figure 1. A representative structure of mammalian brain containing the sources and
the major pathways of cholinergic neuronal projections (i.e., basal-forebrain
cholinergic neurons and pedunculopontine–lateral dorsal tegmental neurons) (adapted
from Felten and Shetty).17

Nicotinic acetylcholine receptors (nAChRs) are one of two major classes of receptors
responsible for cholinergic neurotransmission in the central nervous system (CNS).18
Cholinergic neurotransmission first requires the assembly of the neurochemical mediator,
acetylcholine (ACh), by the synthetic effect of choline acetyltransferase (CAT) in
presynaptic cholinergic neurons. The neurotransmitter ACh interacts with nAChRs as
well as with the other class of receptors in the cholinergic system, muscarinic
acetylcholine receptors (mAChRs).18 While mAChRs are metabotropic G-protein-
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coupled receptors (GPCRs) that produce excitatory or inhibitory responses, nAChRs are
ligand-gated ion channel receptors (LGICRs) in which the excitatory response is
achieved by increased cellular sodium (Na+) and calcium (Ca2+) levels.18
Nicotinic AChRs are highly expressed in human brain in the synaptic region and
other extrasynaptic

locations.19

In

the

synapse,

presynaptic

nAChRs

regulate

neurotransmitter release whereas postsynaptic nAChRs allow the excitatory transmission
process.19 Extrasynaptic nAChRs influence many neurotransmitter systems by mediating
intracellular signals as well as neuronal excitability.19
Nicotinic AChRs are members of the Cys-loop family of LGICRs.20 Members of the
Cys-loop receptor family are formed by the assembly of five identical (homomeric) or
different (heteromeric) subunits (i.e., pentamers).20,21 Each subunit consists of three main
domains (Figure 2): a large extracellular N-terminal domain (ECD), four transmembranespanning helices (i.e., the transmembrane domain (TMD), M1–M4), and an intracellular
domain (ICD).20,21 The ECD consists of 10 β-strands and the loops connecting them. The
sixth and the seventh β-strands are constrained by a disulfide bond connecting two highly
conserved cysteine residues. This highly conserved Cys-Cys bridge is what gives the
family its name.20
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Figure 2. Structural representation of a nAChR model. (A) A whole receptor
representation including the three main domains obtained from PDB (PDB ID: 2BG9);
the ECD, the TMD domain, and the ICD. (B) A top view of five different colored
subunits forming the receptor. (C) The orthosteric binding site formed by loops
located at the interface between the two subunits; the principal subunit ribbon colors:
red, loop A; blue, loop B; yellow, loop C; the complementary subunit ribbon colors:
green, loop D; orange, loop E; purple, loop F.
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Generally, nAChRs can be divided, based on subunit composition, into two general
types, neuronal nAChRs (NnAChRs) and muscle-type nAChRs (MnAChRs).22
Considering the seventeen nAChR subunits of vertebrate species that have been
identified (i.e., α1- α10, β1-β4, γ, δ and ε), various families of nAChR subtypes can be
formed by different subunit combinations.23 All of these subunits are present in humans
as well as in other mammalian species except α8 that exists only in avian species. The
muscle-type nAChRs are composed of two α1 subunits as well as β1, γ, and δ subunits.
The latter is replaced by ε subunits in the adult-neuromuscular junction of vertebrates.24
Conversely, isoforms that form the neuronal-type of nAChRs are composed of certain
subunits (i.e., α2-7, 9, 10; β2-4) and can exist as heteropentamers (e.g., α4β2) or,
sometimes, as homopentamers (e.g., α7, Figure 2). The α4β2 receptors are the major
population of nAChRs in mammalian brain; the α7 receptor subtype is considered the
second most abundant nAChR in the central nervous system.23 On the other hand, a
common heteromeric nAChR (i.e., α3β4) represents the most abundant type of nAChR in
autonomic ganglia, adrenal medulla, and in the dorsal medulla, pineal gland, medial
habenula, nucleus interpeduncularis, and retina.23,25
Although α7 nACh receptors are well-known to be cation-permeable (Na+ and Ca2+)
homopentamers,18 there is also emerging evidence that α7 nAChRs can form
functionally-active heteropentamers with β-subunits.26,27 The binding site of the
endogenous ligand ACh (i.e., the orthosteric site) is located at the interface of ECDs of
every two adjacent subunits in homomeric receptors.25 Upon agonist binding, α7 nAChRs
are characterized by extremely fast activation (<5 milliseconds (ms)) and rapid
desensitization (<100 ms).25 The α7 nAChRs are also known, among other nAChR
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subtypes, by their high permeability to calcium, thus triggering a series of intracellular
calcium-dependent systems.19
As will be discussed in a subsequent section, α7 nAChR ligands are viable
therapeutic agents, however, there is a lack of commonly available selective α7 nAChR
competitive agonists and classical antagonists (i.e., competitive antagonists).24 However,
current attempts in the development of α7 nAChR-selective ligands are confronted with a
considerably high sequence homology of the orthosteric binding sites among nAChR
subtypes.28,29 The lack of subtype-selectivity for nAChR drugs often leads to multiple
cholinergic side effects and thus prevents them from being used as therapeutic agents.
Furthermore, the limited availability of nAChR-selective ligands has hindered progress
toward a complete understanding of the essential functions of different nAChR
subtypes.29
Competitive antagonists, by definition, maintain the inactive state of receptors. To
understand the deactivation process caused by α7 nAChR competitive antagonists,
Monod, Wyman, and Changeux proposed a model (i.e., the MWC model) explaining the
nature of protein allosteric transitions.30,31 Receptors are dynamic structures that can exist
in different states (i.e., distinct functional conformations). For α7 nAChRs, four different
states are possible under normal conditions (Figure 3). The binding of α7 nAChR
competitive antagonists shifts the equilibrium and stabilizes the receptor‘s conformation
to the inhibition/desensitization state.32
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Figure 3. Different nAChR conformations according to the MWC model that explain
the allosteric nature of the receptor: the resting state (R), the active state (A), the fastonset desensitized state (I), and the slow-onset desensitized state (D). Adapted from a
review by Jensen et al.24
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B. α7 nAChR Agonists

Naturally-occurring alkaloids represent an old class of nonselective and high-affinity
agonists for nAChRs. Compounds such as (-)-nicotine (1), (-)-lobeline (LOB; 2) and (±)epibatidine (EPI; 3) (Figure 4) are some members of this class that have been extensively
investigated to understand their molecular role in activating nAChRs.24,33,34 The
selectivity of agonists for α4β2 and α7 nAChRs was found to be highly dependent on the
local binding forces and the long-range electrostatic interactions between the protonated
portion or the cationic part of the agonist structures and the receptors.35 For example, a
conformationally restricted analog of ACh (i.e., 4; Figure 4), is a highly selective full
agonist at the α7 nAChRs (Ki = 92 nM) over α4β2 nAChRs (Ki = 16,000 nM).35 Detailed
information of ligand-receptor attractive forces could guide the design for novel, highly
selective agonists targeting nAChR subtypes.34
An important focus of medicinal chemistry studies in the field of nAChRs was on a
series of novel compounds derived from the nicotine (1) and epibatidine (3) skeletons.
For

example,

substitution

of

the

pyrrolidine

ring

of

nicotine

with

an

azabicyclo[3.2.2]nonane ring (i.e., TC-1698; 5) (Figure 4) resulted in a compound with
full agonist activity at α7 nAChRs (EC50 = 0.44 µM) with insignificant activities at other
nAChR subtypes.24 However, the synthesis of novel α7 nAChR agonists still faces a
selectivity challenge due to the well-known cross-activity with 5-HT3 receptors.24 This
cross-activity results from the high homology in the orthosteric site between the two
receptor types. The 5-HT3 receptor antagonist tropisetron (6) (Figure 4), for instance,
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Figure 4. The chemical structures of selective and nonselective α7 nAChR agonists: ()nicotine (1), (-)lobeline (LOB; 2), (±)epibatidine (EPI; 3), ACh-restricted analog (4),
TC-1698 (5), tropisetron (6), PNU-282987 (7), and GTS-21 (8).
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acts as a partial agonist at α7 nAChRs (EC50 = 0.38 µM).24 Tropisetron has higher
binding affinities (more than 1000-fold) at 5-HT3 and at α7 nACh receptors than at α4β2
and muscle-type nAChRs; however, tropisetron is not selective for the α7 nAChRs since
it antagonizes α3β4 nAChR signaling.24 Nevertheless, a new generation of quinuclidine
analogs, such as the p-chlorobenzamide analog PNU-282987 (7), are highly selective α7
nAChR agonists (EC50 = ~3 µM).24 Moreover, the anabaseine analog GTS-21 (8) is
considered the prototypical selective partial agonist of the α7 nAChRs (EC50 = 6 µM).24
The ACh precursor and metabolic product, choline, produces selective-full agonist
activity at α7 nAChRs (EC50 = ~1000 µM).24,34

C. α7 nAChR Antagonists

Antagonists of α7 nAChRs are represented by a large group of structurally
heterogeneous compounds, and most have been obtained from natural sources. The need
for α7 nAChR antagonists is highly appreciated in animal studies and tissue cultures.
Potent and selective α7 nAChR antagonists can provide optimal settings to precise
detection of different receptor-effects in multiple receptor systems. Several naturally
occurring toxins represent ideal examples of compounds antagonizing ACh at α7
nAChRs. Furthermore, the inhibitory activity of some drugs on α7 nAChRs was
identified as an adjuvant effect of their main pharmacological effect.
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1. Competitive Antagonists

1. Peptides
Although several peptides were identified as antagonists for nAChRs, the majority of
these toxins show inhibition in all subtypes of neuronal nAChRs.36 For example,
neosurugatoxin and lophotoxin are two peptides recognized as non-selective nAChR
inhibitors. There is, however, a minor group of peptides that show selectivity toward α7
nAChR binding. The two particular peptides best-known to selectively antagonize α7
nAChRs are: α-Conotoxin, a peptide that belongs to the conotoxin group that is known to
be a cysteine-rich peptide extracted from cone snails (Conus pennaceus),37 and αbungarotoxin,38,39 a venom that is extracted from the Taiwanese krait Bungarus
multicinctus. Although these two groups of peptides are highly specific to nAChRs, their
interactions with the receptors are irreversible.39 This significant binding property has
been exploited in the standardization of experimental procedures to isolate nAChRs from
the electric organs of the marine ray Torpedo.38,40 Consequently, extensive knowledge of
the diversity and molecular properties of receptors have been identified due to
developments in molecular biology techniques.
Due to their size and physicochemical properties, both α-conotoxin and αbungarotoxin do not pass biological barriers such as the gastrointestinal (GI) tract and
blood–brain barrier (BBB).41 The structures of these peptides lack drug-like properties,
and this limits their use as therapeutic agents. The disadvantages of peptides has led to an
effort to identify alternative small molecules that have better pharmacokinetic features
(i.e., absorption, distribution, metabolism and elimination (ADME)) in humans.42
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2. Methyllycaconitine

Methyllycaconitine (MLA; 9) (Figure 5) is a naturally occurring norditerpenoid
alkaloid isolated from the Delphinium and Consolida species.43 MLA is a competitive
antagonist for α7 nAChRs (IC50 = 0.0017 µM) and is the standard α7 nAChR antagonist
in pharmacological studies.24,44 The binding of MLA is relatively selective for α7
nAChRs (Ki value of 5-10 nM), although it possesses moderate binding affinity for α3β4
and α4β2 nAChRs (Ki value of around 1,300 nM).24,38
The therapeutic utility of MLA is limited because of its large molecular mass and
narrow therapeutic index.45 Thus, the typical use of MLA is as an experimental tool for
investigating the pharmacological properties and the heterogeneity of nAChRs. In
binding studies, the sensitivity to low nanomolar concentrations of [3H]MLA has been
interpreted as an indication for the presence of α7 nAChRs.46,47 Other pharmacological
experiments indicate that, when MLA potently inhibits presynaptic nAChRs, it blocks the
mediation of [3H]dopamine release from striatal synaptosome sites.43,47 Furthermore,
MLA has been utilized as a lead compound for the identification of novel nAChR
antagonists, considering the structural components of MLA that might produce favorable
features for the newly proposed nAChR ligands.48,49
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Figure 5. The chemical structures of selective and nonselective α7 nAChR
antagonists: methyllycaconitine (MLA; 9) and memantine (10), respectively.
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3. Memantine

Memantine (10; Figure 5) is a low molecular-weight drug, presently approved by the
Food and Drug Administration (FDA) for symptomatic treatment of moderate-to-severe
AD. The approval of this drug is based on its ability to noncompetitively antagonize
NMDA receptors.38,50 Beside this pharmacological action, memantine was shown to be
an α7 nAChR antagonist (IC50 = 0.34 µM). While some50 consider the effect on α7
nAChRs as an undesired property that might worsen the condition of AD patients,
Banerjee et al.51 considered this inhibitory activity as an advantageous action. However,

!

17!

!

more experiments are needed to clarify the significance of memantine’s inhibitory
activity on α7 nAChRs for AD. In any event, memantine certainly cannot be considered
as an α7-selective agent.

2. Non-Competitive Antagonists

Non-competitive antagonists (NCAs) are a class of compounds that inhibit the
activity of receptors by interacting with sites distinct from the agonist’s binding site, and
therefore do not compete with agonists for binding. Since the action of NCAs is not
surmountable by agonist, there are two possible mechanisms by which NCAs can exert
their activity on nAChRs. The first possible mechanism is through direct blockade of the
receptor’s channel (i.e., channel blockers). Channel blockers are characterized,
pharmacologically, by blocking the receptor’s currents in a voltage-dependent manner.52
On the other hand, NCAs can inhibit the receptor activity in a voltage-independent
manner (i.e., negative allosteric modulators (NAMs); discussed in the next section).52
NAMs exert their activity on nAChRs without blocking the receptor’s channel.
A typical example of an NCA for neuronal nAChRs is the synthetic compound
mecamylamine (11; Figure 6).52,53 Mecamylamine blocks the ion-channel of most
neuronal nAChRs with more sensitivity toward α/β heteromers than α7 nAChRs, which
requires 10 µM for full blockade.53 Another example of channel blockers of α7 nAChRs
is naltrexone (12; Figure 6) (IC50 ~ 25 µM).54 In addition to its opioid antagonist activity,
naltrexone shows a voltage-dependence effect on the α7 nACh receptor currents.54
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Figure 6. The chemical structures of two channel blockers of α7 nAChRs:
mecamylamine (11) and naltrexone (12).
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D. Positive Allosteric Modulators

Allosteric modulators are those ligands that interact with the receptor’s allosteric sites
and modify either or both the binding and the signaling of the orthosteric ligand.
Allosteric modulators have no intrinsic channel activation properties and, thus, their
pharmacological function is to modify normal receptor mechanisms.55 Both type of
allosteric modulators (i.e., positive allosteric modulators or PAMs, and negative allosteric
modulators or NAMs) are believed to alter the energy barriers for state transitions and/or
stabilize the relative energy levels of particular receptor states.55,56 Consequently,
modulation of receptor activity involves not only the stabilization of channel
opening/closing states but also the kinetics of activation, deactivation, desensitization, or
resensitization (Figure 3).
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Once an agonist associates with the receptor, it induces a conformational transition
(Figure 3) from a resting state (channel closed) to an activated state (channel open).57 For
α7 nAChRs, a conformational transition to a desensitized state (channel closed) is
expected in less than one second, if the agonist remains bound. In order for the receptor
to return to the resting state, the agonist must dissociate.57 The variety of structures of α7
nAChR allosteric modulators alter this system with mechanistically distinguishable
modes that, eventually, can be observed in the different forms of the agonist-evoked
inward currents.57,58
Based on the pharmacological profiles of structurally distinct α7 nAChR modulators,
two types are recognized.59 Type I PAMs predominantly increase agonist response
amplitude without significant effect on response decay rate. Type II PAMs enhance
response amplitude and also reduce receptor desensitization, allowing fast reactivation
from the desensitized state. Given the intricacies of LGIC states and kinetics, it should be
anticipated that more than one mechanism could underlie the broad modulator categories
identified to date.57 In addition to these two types, some identified PAMs display
exceptional properties that are intermediate between the type I and type II classes.57-59
The definition of an allosteric modulator for α7 nAChRs is also applicable to
polypeptides that have been found to significantly enhance the ACh-evoked currents. The
Ly-6/uPAR related protein 1 SLURP-1 (secreted by human keratinocytes) and the C
terminus peptide fragment of acetylcholinesterase (AChE) are found to be highly
selective PAMs at the human α7 nAChRs.60,61 However, because of their size and
physicochemical properties, these agents cannot cross the blood brain barrier and are not
useful as for exploring their pharmacological actions for in vivo studies.62 This issue
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signifies that the development of small molecule modulators is a promising approach in
medicinal chemistry.

1. Extracellular Domain (ECD) PAMs

i.

Galantamine

Galantamine (Gal; 13) (Figure 7), an alkaloid originally isolated from snowdrop
flowers, is an FDA-approved drug for symptomatic treatment of mild-to-moderate AD
and has been also tested as an adjuvant therapy to improve cognitive function in
schizophrenia.63-65 The approval of this drug is based on its ability to inhibit the
cholinesterase enzyme, which is responsible for the breakdown of ACh. Besides this
pharmacological action, galantamine was shown to have a synergistic effect at α7
nAChRs through an allosteric-modulating mechanism.66,67 Galantamine is considered a
type I PAM since it does not affect the desensitization time of α7 nAChRs.24,55
The location at which galantamine binds on α7 nAChRs has been extensively
investigated using photoaffinity labeling, epitope mapping studies with the monoclonal
antibody (mAb) FK1, and site-directed mutagenesis studies.68-70 These studies identified
the location of the binding site to be at the outer surface of the ECD, in an area that
overlapped with the ACh site. Three amino acid residues (i.e., Val196, Thr197, and
Phe198) located on β-strand 10 of the α7 subunit can weaken galantamine binding after
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mutation. From these three residues, only Thr197 appeared to be an essential attachment
point since its mutation influenced binding the most.70

ii.

Physostigmine

Like galantamine, physostigmine (14; Figure 7) shows a dual mode of action, as a
cholinesterase inhibitor (AChEI) and PAM.68,69 Historically, physostigmine showed the
ability to enhance memory in normal individuals as well as in patients suffering
dementia.71 However, the very short half-life of physostigmine (t1/2 ~ 30 min) limited its
use as a memory protective agent.72 Currently, the FDA-approved use of physostigmine
is to reverse the anticholinergic effects of toxic doses of cholinergic drugs.
The binding site location of physostigmine at α7 nAChRs was identified using
epitope mapping studies with the FK1 monoclonal antibody and photoaffinity labeling
studies with physostigmine.68-70 Furthermore, physostigmine binding was blocked by the
mAb FK1 which indicates the same general area as the galantamine binding site.69
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Figure 7. The chemical structures of PAMs of α7 nAChRs: galantamine (13),
physostigmine (14), PNU-120596 (15), and ivermectin (16).
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2. Transmembrane Domain (TMD) PAMs

a. PNU-120596

1-(5-Chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea or PNU-120596
(15; Figure 7) is an α7 nAChR PAM that was originally discovered by high-throughput
screening.73 PNU-120596 is considered a type II PAM since it has the ability to enhance
peak ACh-evoked currents and slow the response decay rates in cells expressing α7
nACh receptors.73 Moreover, there is a remarkable selectivity of PNU-120596 for α7
nAChRs with no significant effect on most other subtypes of nACh receptors.73
Many efforts targeting the identification of the exact binding site for PNU-120596 at
α7 nAChRs have been reported. Evidence shows that the intrasubunit cavity in the TMD
of α7 nAChRs is the potential location for the PNU-120596 interaction.74,75 Furthermore,
mutagenesis studies indicate that the amino acids Ser222 and Ala225 from M1, Met253
from M2, and Phe455 and Cys459 from M4 have essential attachment points with PNU120596.74

b. Ivermectin

Ivermectin (16; Figure 7) is a macrocyclic lactone derivative of a natural compound
that can be isolated by fermentation of the soil microorganism Streptomyces avermitilis.76
Ivermectin is available in the market as an antiparasitic agent in both human and
veterinary medicine.77 The antiparasitic effect of ivermectin is believed to result from its
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agonist activity on glutamate-gated chloride channels as the major target.78 Additional
biological targets of ivermectin include the modulation of multiple LGICR actions such
as its positive modulatory activity on human α7 nAChRs.79 Unlike PNU-120596,
ivermectin modulation is considered as a type I PAM.
Ivermectin, however, shares a similarity with PNU-120596, in that mutagenesis
studies indicated the potential location for ivermectin interaction at α7 nAChRs to be at
the large intrasubunit cavity in the TMD.80 Moreover, the amino acids Ala225 from M1,
Gln272 from M3, and Thr456 and Cys459 from M4 have essential attachment points with
ivermectin.80 Interestingly, mutations of three amino acids (S222M, M253L and S276V)
were able to convert ivermectin from a PAM into a NAM.80

E. Negative Allosteric Modulators

Another approach to inhibiting the action of ACh at α7 nAChRs is to identify an
allosteric modulator that selectively deactivates the receptors (i.e., negative allosteric
modulators (NAMs)). As described previously, allosteric modulators are receptor ligands
that interact with sites distinct (i.e., allosteric sites) from the orthosteric site and mediate
either or both the binding and the signaling of the orthosteric ligand.25 The mechanism of
allosteric modulations has been extensively studied and was clinically initiated by the
binding of benzodiazepines at the allosteric binding site of GABAA receptors.81 For α7
nAChRs, allosteric modulators tune up (i.e., PAMs) or tune down (i.e., NAMs) receptor
activity when the endogenous neurotransmitter ACh is present.82 NAMs are different
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from classical antagonists where direct binding to the orthosteric site and a continuous
effect occurs, regardless of normal neuronal activity. Allosteric modulators have unique
advantages, such as the saturability of the allosteric site, which provides better control
over the administered agent.82,83 While classical agonists and antagonists can cause
extreme stimulation or inhibition of the receptor, an allosteric modulator has a maximal
ceiling.83 This advantage reduces any undesired effects (e.g., toxic effects) that might
interfere with the desired effect.82,83 Another advantage is that an allosteric modulator is
expected to work only at a time when an endogenous agonist is present at the orthosteric
site.83 By this feature, the allosteric modulator effect would vary depending on the
neuronal tone and the tissue state, which apparently differs from that of the orthosteric
ligand that works in a continuous fashion irrespective to neuronal activity.83,84 A third
advantage is the receptor subtype selectivity of allosteric ligands over classical
orthosteric ligands and this is because the orthosteric sites of nAChRs are the most
conserved region among this receptors subtype.20,83,84
The main problem in the development of a drug discovery program toward
noncompetitive inhibitors of nAChRs is the difficulty of identifying and quantifying
allosteric modulators. Allosteric modulators are impossible to design a priori and
serendipity is the common route of their identification.8,24,55,85,86 The current standard
experimental approach for the determination of a noncompetitive inhibitor’s activity at
nAChRs involves the use of concentration-dependent methods on whole cell currents87 or
the nicotine-induced

86

Rb+ cellular efflux model system.88 These approaches do not

satisfy the requirement of efficient drug discovery practices as they are expensive, timeconsuming, and cannot be generalized to all nACh receptor subtypes.89 Even the use of
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an efficient approach, such as displacement chromatographic techniques, assumes the
existence of known competitive displacers.90 To date, several allosteric sites on nAChRs
have been identified, including three major sites that are present on all nAChR
subtypes.89 Moreover, a wide variety of structurally diverse allosteric modulators of
nAChRs have been reported over the last decade.8,24,55,85,86
Allosteric ligand NAMs have gained great attention lately for their potential clinical
applications. The primary effect of NAMs is to elevate the energy barrier between the
receptor’s active and resting states.56 Medicinal chemistry efforts to identify novel
allosteric ligands that selectively antagonize nACh receptor function are required.
Kynurenic acid (KYNA; 17) (Figure 8) is a tryptophan metabolite, produced mainly
in astrocytes, that has long been recognized as an NMDA receptor antagonist.91 It was not
until recently that evidence showed KYNA at nanomolar concentrations, the normal level
in the brain, to be the first endogenous negative allosteric modulator at α7 nAChRs, and
that this can cause a marked reduction in striatal DA.92 These concentration limits are not
enough to exert activity at the NMDA receptor. Another NAM of α7 nAChRs reported
by Yoshimura et al.,81 UCI-30002 (18; Figure 8), was discovered through a library
screening of subtype A of the γ-aminobutyric acid (GABAA) receptor’s modulators for
nAChRs. However, this compound lacks selectivity, and no evidence of its action as a
NAM at α7 nAChRs was provided. Abdrakhmanova et al.93 reported in 2010 that
1,2,3,3a,4,8b-hexahydro-2-benzyl-6-N,N-dimethylamino-1-methylindeno[1,2,-b]pyrrole
(HDMP; 19) (Figure 8) is a potent and selective NAM for α7 over α4β2 and α3β4 nACh
receptors (IC50 = 0.07 µM).
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Figure 8. The chemical structures of NAMs of α7 nAChRs: kynurenic acid (KYNA;
17), and UCI-30002 (18), HDMP (19), and meta-chlorophenylguanidine (MD-354;
20).
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meta-Chlorophenylguanidine (MD-354; 20) (Figure 8) was reported by our
laboratory8,94 as the first subtype-selective small molecule to function as a NAM at α7
nAChRs. MD-354 (20) does not bind at the orthosteric site of α4β2 (Ki > 10,000 nM) or
α7 nACh receptors (Ki > 100,000 nM) but blocks the antinociceptive effect of the agonist
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nicotine in the mouse tail-flick assay.8 Electrophysiological studies, using the whole-cell
configuration of the patch-clamp technique to obtain functional data at stably transfected
human embryonic kidney (HEK) 293 cells expressing rat α7 nAChRs, showed that MD354 (20) is a noncompetitive α7 nACh receptor antagonist (IC50 = 7.98 µM).8 The NAM
activity of MD-354 (20) was confirmed through the elimination of possible competitive
antagonism activity since competitive antagonists do not produce inhibition at currents
evoked by an ACh-saturated concentration (Figure 9A). Also, the elimination of possible
channel blocking activity was achieved by showing that MD-354 (20) produces a
voltage-independent effect at various holding potentials (Figure 9B). However, MD-354
(20) has been found to act as a partial agonist (in an in vivo model) at 5-HT3 receptors (Ki
= 35 nM), in addition to its NAM activity at α7 nAChRs.8,95 The origin of the crossreactivity of many α7 nAChR and 5-HT3 receptor ligands is due to the high homology (~
30%) between the two receptor types, which is considered as the highest similarity within
the LGIC superfamily.96
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(A)

(B)
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Figure 9. The inhibitory effects of MD-354 (20) at 10 µM at α7 nAChRs. (A) The
inhibitory effects of MD-354 on α7 nAChRs at an EC50 concentration of ACh (i.e.,
280 µM) and at a saturated concentration of ACh (i.e., 1 mM). (B) The inhibitory
effects at various holding potentials in the range from -100 to +30 mV. The upper part
represents superimposed traces of ACh-induced currents in the absence and presence
of 20. In the lower part, squares represent the maximal amplitude in the absence of 20
plotted versus the corresponding holding potential, whereas circles represent the
maximal amplitude in the presence of MD-354 (20) at a concentration around its IC50
value plotted versus the corresponding holding potential.8,9
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! Arylguanidine SAR for 5-HT3 receptor binding affinity showed that introduction of

certain aryl substituents reduces the 5-HT3 receptor affinity of MD-354 (20) (Ki = 35 nM)
(i.e., 21, 22, 23 (Figure 10); Ki = 2,340, 2,440, 1,600 nM; respectively) and that Nmethylation of the aniline nitrogen atom (i.e., 24; Figure 10) resulted in a significant
reduction in affinity (Ki = 6,200 nM) as well.94,95 Although these structural alterations
of MD-354 (20) are detrimental to 5-HT3 receptor binding, there is no reason to believe
that the inhibitory activity (i.e., NAM action) at α7 nACh receptors will be affected.
Based on this assumption, the inhibitory activity (i.e., IC50 values) at α7 nACh receptors
of compounds 20 - 24, were obtained (Table 1).8,94,95 The resulting IC50 values showed
that when the chloro group of MD-354 (20) is removed, potency is decreased (i.e., 21,
IC50 = 34.84 µM). In the same manner, inhibitory potency is reduced when the chloro
group of 20 is replaced with the more electron-withdrawing –CF3 group (i.e., 22; IC50 =
18.46 µM).
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Figure 10. Chemical structures representing different modifications of the MD-354
(20) structure. 5-HT3 receptor affinity is provided [in brackets] as Ki values.94,95
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Table 1. The IC50 values of MD-354 (20) and analogs for α7 nACh receptors, and their
affinities at 5-HT3 serotonin receptors.

Compound

X

R

α7 nAChR
IC50 ± SEM
(µM)

20

H

Cl

7.98*____

21

H

H

34.84 ± 6.85

2,340

22

H

CF3

18.46 ± 0.42

2,440

23

H

OCH3

7.54 ± 0.74

1,600

24

CH3

Cl

1.26 ± 0.26

6,200

NH
X

N

NH 2

5-HT3 R
Ki
(nM)**
35

R

*

!

α7 nAChR IC50 value of 20 reported by Dukat et al.8

**

5-HT3 receptor Ki values reported by Dukat et al.94,95

Compound 23 (IC50 = 7.54 µM), where –OCH3 is an electron donating group at the 3position of the phenyl ring, showed a potency comparable to that of MD-354 (20) at α7
nACh receptors; however, its low affinity at 5-HT3 receptors makes 23 a more selective
α7 nACh receptor inhibitor than 20. A major increase in potency at α7 nACh receptors is
shown by the N-methyl analog of MD-354 (i.e., 24; IC50 = 1.26 µM) (Figure 11).9
Compound 24 exhibits a more than 1,000-fold shift in selectivity (5-HT3 receptor Ki =
6,200 nM) and higher potency at α7 nACh receptors compared to 20 (5-HT3 receptor Ki =
35 nM).9 Moreover, the NAM activity of 24 was confirmed through the elimination of
possible competitive antagonism activity (Figure 12A) and the elimination of possible
channel blocking activity (Figure 12B).9 Thus, it was demonstrated that the structural
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requirements of the arylguanidines for 5-HT3 receptor binding, and actions as α7 nAChR
NAMs, are not inextricably linked.
!
!

(A)

!
!
!
!
!
!

24

!
!

(B)

!

24

!
!
!
!
!
! Figure 11. Functional description of the N-methyl analog of MD-354 (i.e., 24) activity

at α7 neuronal nAChRs.9 (A) A concentration–response relationship for different
concentrations of 24 at α7 nAChRs where peak amplitude due to exposure to ACh
(EC50)-evoked currents was normalized. The Hill equation was applied to the curve,
and the symbols and bars represent the mean ± SEM. (B) The inhibitory effect of 24 at
a concentration of 1 µM. The recorded results in (A) and (B) were performed at a
holding potential of −80 mV.
!

34!

!

(A)

(B)

24

24

(C)
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Figure 12. The inhibitory effects of 24 at 1 µM at α7 nAChRs.9 (A) The inhibitory
effects of 24 on α7 nAChRs at an EC50 concentration of ACh (i.e., 280 µM) and at a
saturated concentration of ACh (i.e., 1 mM). (B) The inhibitory effects at various
holding potentials in the range from -100 to +60 mV. This represents superimposed
traces of the ACh-induced currents in the absence and presence of 24. (C) The squares
represent the maximal amplitude in the absence of 24 plotted versus the corresponding
holding potential, whereas circles represent the maximal amplitude in the presence of
24 at a concentration around its IC50 value plotted versus the corresponding holding
potential.
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The activity of 20 - 24 at a fixed concentration of 10 µM at α3β4 nACh receptors was
investigated to test the selectivity of these compounds among nAChR subtypes (Figure
13).9 MD-354 (20) showed a lack of activity at 10 µM concentration on ACh at α3β4
currents at α3β4 nAChRs relative to ACh EC50 = 100 µM (Figure 20), whereas 31 and 40

nAChRs
relative totheACh
its 50EC
concentration
(EC50 = Compounds
100 µM) (Figure
whereas
slightly attenuated
AChat(EC
= 50100
μM)-evoked currents.
45 and 14),
46 reduced
current
of ACh to
a differentthe
extent.
21theand
24 slightly
attenuated
ACh (EC50 = 100 µM)-evoked currents. Compounds 22

and 23 reduced the current of ACh to a different extent.9
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Figure 13. Effect ± SEM of 20, 21, 22, 23 and 24 at 10 µM concentration on

Figure 19. Mean effect of 21, 31, 40, 45 and 46 at 10 µM concentration on acetylcholine (ACh)

acetylcholine
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to current
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function
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nAChRsfunction
relative toatACh
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(A)

(B)

Figure 14. A) The effect of ACh (EC50 = 100 µM)-evoked current at α3β4 nAChRs. B)
The effect of MD-354 (20) at 10 µM concentration on ACh (EC50 = 100 µM)-induced
current at α3β4 nAChRs.9 Holding potential for these recording was - 80 mV.
!

MD-354 (20) neither displayed affinity (Ki > 10,000 nM) nor possessed functional
activity at α4β2 nAChRs.9 The activity of 20, as well as 24, at α4β2 receptors was
investigated as part of the selectivity test of these compounds among nAChR subtypes
(Figure 15).9 Both compounds at concentrations comparable to the IC50 for α7 neuronal
nACh receptors showed no activity on ACh (EC50 = 20 µM) at α4β2 nACh receptors. In
addition, both compounds were examined for their agonist activity at α4β2 nACh
receptors at their respective IC50 concentrations and failed to mimic ACh actions.9
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(A)

(B)

(C)

(D)

24

24

24

Figure 15. Effect of MD-354 (20) and 24 on α4β2 nAChRs.9 (A) Effect of ACh at
EC50 = 20 µM and saturated concentrations = 1 mM. (B) Effect of MD-354 (20) on
ACh (EC50 = 20 µM)-evoked current and by itself at α4β2 nAChRs. (C) Effect of ACh
(EC50 = 20 µM) alone and effect of ACh at EC50 = 20 µM accompanied by 10 µM of
24. (D) Effect of 24 at 1 µM on ACh (EC50 = 20 µM)-evoked current and by itself at
! α4β2 nAChRs. Holding potential for these recording was - 80 mV.
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Further investigations for the required structural features of these small-molecule
were applied to determine and optimize their NAM activity at α7 neuronal nAChRs.9
Considering the functional data from MD-354 (20) and its N-methyl analog 24, since the
N-methyl group is known to be detrimental to 5-HT3 receptor binding, a new series of
compounds was synthesized.9 The chloro group at the 3-position of N-(3-chlorophenyl)N-methylguanidine (24) was replaced with a number of substituents considering the
electronic, the lipophilic, and the steric nature of the new substituent (Table 2).9 In
addition, the activity of any new modification at α7 nACh receptors was compared to that
determined for the same modification in the MD-354 series to test if parallel structural
modification would result in parallel change in activity, which might suggest whether or
not the two series bind at the same manner (Table 2).9
The functional data on two compounds of each series (i.e., 20 and 21 of MD-354
series, and 24 and 25 of the new N-methyl series) revealed the inhibitory activity of these
compounds at α7 nACh receptors.9 Removal of the chloro group from 20 (i.e., 21)
resulted in around a four-fold reduction in the current (Table 1). In contrast, removing the
chloro group from 24 (i.e., 25; IC50 = 30.81 ± 2.13 µM)9 results in around a thirty-fold
reduction of its effect. However, the number of compounds tested here might not be
sufficient to confirm that the N-methyl series binds in the same manner with α7 nAChRs
as MD-354 series.9 The possibilities that the N-methyl series might bind to a different
allosteric site than that of the MD-354 series, or that the N-methyl series could bind to the
same allosteric site as that of the MD-354 series, remain to be considered.
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Table 2. Structural representation and substituent constants of the N-methyl series and
the MD-354 series of arylguanidines.

NH

NH
H 3C

NH 2

HN

NH 2

N

X

a

!

X

MD-354

N-methyl

Series

Series

Compound

R

πa

σm a

Compound

20

Cl

0.71

0.37

24

21

H

0.00

0.00

25

31

Br

0.86

0.39

26

32

F

0.14

0.34

27

33

I

1.12

0.35

28

34

CH3

0.56

-0.07

29

23

OCH3

-0.02

0.12

30

π and σm aromatic R substituent constants reported by Hansch et al.97!
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F. Clinical Implications of α7 nAChR Ligands

The discovery of small molecules that influence α7 nAChR activity would be of great
importance. As research tools, they would enhance our understanding of the roles that
nAChRs play in physiological and pathological states. Furthermore, they hold clinical
promise as therapeutic agents for disorders associated with nAChRs.

1. Alzheimer’s Disease

Alzheimer’s disease (AD) is a neurodegenerative disorder associated with a slow and
progressive loss of memory and cognition.98 The neuropathology of AD is characterized
by the presence of two types of abnormal deposits, cortical senile (amyloid) plaques (SP)
and neurofibrillary tangles (NFT) that, consequently, cause extensive neuronal loss.98
Evidence showed that α7 nAChRs mediate the pathology that leads to the formation of
these AD hallmarks.98,99
Controversially, both agonists and antagonists of α7 nAChRs can offer benefits not
only for symptomatic therapy, but also for decreasing the progression of AD.100,101
Apparent explanation of the desired effects of agonists might be related to the fact that α7
nAChRs desensitize (i.e., reducing cholinergic transmission) rapidly after exposure to
agonists such as nicotine.100,102 Conversely, antagonists directly attenuate nAChRmediated transmission.100-102 Another explanation suggests that α7 nAChR ligands
prevent the toxic effect of the high-affinity binding of β-amyloid peptide 1-42 (Aβ1-42) to
the α7nAChRs and, consequently, prevent Aβ1-42 cellular internalization.101
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Current clinically approved drugs to treat mild-to-moderate AD cause inhibition of
acetylcholinesterase, the enzyme responsible for the hydrolysis of the neurotransmitter
ACh.103 These drugs include galantamine (13; Figure 7), donepezil, and rivastigmine
(structures not shown). These drugs, when co-administered with other therapies, show a
reduction in cognitive impairment in small samples of patients with schizophrenia.63,103
Although these results were derived from open, uncontrolled studies, only galantamine
showed positive outcomes when applied as an add-on therapy for a small randomized
sample in a double-blind trial, and no positive results were detected with donepezil or
rivastigmine.63

2. Marijuana Addiction

The nucleus accumbens (NAc) and ventral tegmental area (VTA) are two major
compartments of the mesolimbic dopamine system that are responsible for addictive
properties of abused drugs (Figure 1). Both the NAc shell and the VTA express α7
nAChRs.104 The activation of these receptors causes the release of glutamate and the
activation of ionotropic glutamate receptors, which, consequently, stimulates dopamine
release at dopaminergic terminals.105 There is evidence that animals treated with Δ9tetrahydrocannabinol (THC), the primary constituent responsible for marijuana abuse and
dependence, experience elevation in mesolimbic dopamine transmission, whereas a
reduction in mesolimbic dopamine transmission is observed during drug withdrawal.106
Furthermore, methyllycaconitine (9; Figure 5), a relatively selective α7 nAChR
antagonist, blocks the behavioral rewarding properties and neurochemical actions of
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THC.7 This implies a possible role of modulation by α7 nAChR activity and indicates the
pharmacological potential of α7 nAChR antagonists for treating marijuana dependence.
Inhibition of presynaptic α7 nAChRs was recently investigated as a useful approach
to treat the withdrawal symptoms of marijuana.106 Kynurenic acid (KYNA; 17) (Figure 8)
is an endogenous noncompetitive antagonist at α7 nAChRs.91 Studies showed that KYNA
(17) was capable of lowering extracellular glutamate and, consequently, reduced the
release of dopamine in the striatum and prefrontal cortex.92,106 Therefore, targeting
presynaptic α7 nAChRs with a potent antagonist might provide a valuable tool for the
treatment of drug dependence and other dopamine-related disorders.

3. Depression

Ketamine (Ket; 35) (Figure 16) is a chiral drug known to act as an N-methyl-Daspartate (NMDA) receptor antagonist, but it also acts at numerous other targets
including nAChRs.107 Ket (35) is known clinically for its anesthetic properties; however,
it is associated with several other advantageous properties such as potentiation of the
opioid analgesic effect, an anti-inflammatory effect, anti-tumor effect and antidepressant
effect.107,108 In an effort to study the pharmacological activity of Ket (35) and its
metabolite norketamine (norKet), Moaddel et al.109 investigated their antidepressant
properties using sub-anesthetic dosing of Ket in treatment-resistant patients. Data
indicated that there are strong links between the antidepressant effect and the plasma
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levels of diastereomeric hydroxynorketamine (HNK) and some of the HNK metabolites
that are normally found in circulating blood obtained from patients.109,110 This study also
showed that only one particular isomer (i.e., (2S,6S)-HNK; 36) (Figure 16), out of the
other major metabolites, was the most potent in in vitro studies.109,110 The
pharmacological activity of this metabolite was tested, later, at NMDA receptors, α7
nAChRs, and α3β4 nAChRs and results showed that (2S,6S)-HNK is a potent and
selective NAM at α7 nAChRs with no detection of anesthetic activity in rat.109,110
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Figure 16. The chemical structures of NAMs of α7 nAChRs: ketamine (Ket; 35), and
(2S,6S)-HNK (36).
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Activity at presynaptic α7 nAChRs results in a potential consequence on the activity
of the enzyme serine racemase (SR).111 SR is a Ca2+-dependent enzyme that works to
increase the intracellular level of D-serine (D-Ser). Endogenous D-Ser is a known coagonist of NMDA receptors, and a long-term potentiator that is associated with NMDA-
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induced neurotoxicity.111,112 The inhibition of α7 nAChRs lowers intracellular Ca2+ levels
that, in turn, decreases SR activity and, consequently, endogenous D-Ser levels. Thus,
potent and selective antagonists of α7 nAChRs might represent promising antidepressant
agents through the indirect modulation of NMDA receptor activity.109,110,112

4. Lung Cancer

During the period between 1989 and 1994, several publications described the
presence and the potential importance of nicotinic receptors in lung cancer cells.113-116 In
addition, the presence of ACh and all the required components for its synthesis and
activity such as CAT and nAChRs in human airway epithelial cells widened the
possibility of different pathological roles in the periphery.113-116 Exposure to nicotine
through tobacco smoke or cigarette substitutes can initiate the proliferation of a variety of
small-cell lung carcinoma cell lines and endothelial cells.117,118 This effect is also seen in
structurally-related carcinogens such as 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone
(NNK) and N'-nitrosonornicotine (NNN) which also can reach non-neuronal tissues and
increase the production of growth factors (e.g., TGF-α, and VEGF). These factors
eventually lead to protein upregulation and activation of the Raf/MEK/ERK pathway that
is associated with tumor development and progression.117,118
Numerous laboratories have reported the observed transformations of pharmacologic
doses of tobacco and other carcinogenic nitrosamines on different cell lines.118 In an in
vitro study analyzing the level of gene expression of nAChR subtypes in smokers’ and
nonsmokers’ non-small-cell lung cancer (NSCLC) tissues after 72 hours exposure to
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nicotine (0.1 µM) indicated a significantly reversible upregulation of α1, α5, and α7
subunits in bronchial epithelial cells.119 Other studies reported a major role for α7
nAChRs over other nicotinic receptor subtypes in mediating nicotine’s proliferative
properties in lung tumor cells.120-122 Although there are several studies investigating the
possible mechanisms and the contributing factors for carcinogenesis in different types of
lung tumors, the involvement of nicotinic receptors, in particular α7 nAChRs, represents
a separate and unique therapeutic approach that might provide an unprecedented
opportunity for progress.118

G. Molecular Characteristics of Human α7 nAChRs

The cDNA of the human α7 receptor subunit encodes a polypeptide of 502 amino
acid residues.98,123 The human α7 protein subunit is about 56 kDa and is composed of 222
amino acids forming the ECD, 87 amino acids forming the TMD, and 152 amino acids
forming the ICD.123 Important regions on the primary sequence of α7 nAChR subunit
were identified, including the orthosteric binding site (i.e., loops A, B, C, D, E, and F)
(Figure 17).123 The essential amino acids involved in orthosteric ligand recognition are
Trp171, Tyr115, Tyr217, and the adjacent two cysteine residues (Cys212 and Cys213)
forming the disulfide bond at the C loop.123 There are also the well-known two cysteine
residues (i.e., Cys150 and Cys164) that form the disulfide bond characterizing the Cysloop family of receptors (Figure 17).123
The level of sequence identity between human α7 subunits and the different subunit
classes of the nACh receptors is approximately 41%.124 For interspecies comparison, the
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human α7 subunit is highly conserved, exhibiting 94% and 92% amino acid sequence
identity to rat and chicken receptors (Figure 17), respectively.123 This high sequence
identity implies that there are very few sequence differences among human, chicken, and
rat α7 receptors to account for pharmacological differences between species.
The transmembrane sequences are identical in all three species.123 The M2 sequence
is the transmembrane portion responsible for lining the ion channel and, as expected,
shows an identical amino acid sequence to those of homomers of α7 from chickens and
rats.123 The most sequence diversity is in the large intracellular loop connecting M3 and
M4, as is typical for interspecies sequence variation of nAChR subunits.123
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Figure 17. Multiple sequence alignment of three amino acid sequences (i.e., human,
rat, and chicken α7 nAChR monomers) showing a high degree of identity. Amino acid
residues forming the orthosteric site are: red, loop A; blue, loop B; yellow, loop C (for
the principal subunit ribbon); and green, loop D; orange, loop E; purple, loop F (for
the complementary subunit ribbon).
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H. Previously Reported Molecular Models of Human α7 nAChRs

The significance of molecular modeling, as an important computational tool in drug
design, is widely appreciated.125 The level of structural information to be gained from
these models might provide tremendous insight for interpreting pharmacological data.
Among several interesting biological targets, molecular modeling studies on α7 nAChRs
gained much attention and were reported in a number of scientific papers.74,80,126-129 The
motivation for these studies is to explore and learn more about the structural basis of the
molecular effect on α7 nAChRs through homology modeling and ligand docking. In
addition, molecular information was also obtained from the publication of crystal
structures of similar protein targets that share acceptable sequence identity with α7
nAChRs.129
In 2006, two models of α7 nAChRs were introduced. The first one was by Iorga et
al.126 where they docked three allosteric modulators seeking the identification of their
potential binding site(s) at the ECD (see Table 3). The second model was by Cheng et
al.127 where they studied the gating motion of the receptor. The differences between the
two models was the crystal structure template used for homology modeling.126,127
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Table 3. Summary of previously reported models of α7 nAChRs for identifying possible
allosteric binding sites.
Iorga et al.126

ECD

Template

AChBP
(1UV6)

Cavity Search
Software

Alpha spheres
(MOE)

Blind Docking
Software

AutoDock

Template

TM

Brannigan et al.129

Torpedo m. (2BG9)

Cavity Search
Software

Molecular dynamic
simulation
“flooding”

Blind Docking
Software

Young et al.74 constructed a homology model of human α7 nAChRs in 2008, based
on the 4 Å crystal structure of the Torpedo nAChR. Their aim was to predict the binding
modes of two PAMs (i.e., PNU-120596 and LY-2087101) at the intrasubunit cavity. The
following year, Luttmann et al.128 presented a model for the extracellular portion of the
human α7 nAChR. The model was used to identify possible binding sites for
allosterically-potentiating ligands (APLs) by searching for cavities and blind-docking
experiments with several APLs. Collins et al.80 also used a homology model of the human
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α7 nAChR TMD to investigate the binding modes of ivermectin in 2010. The binding site
was proposed to be in the intrasubunit cavity located between the four transmembrane αhelices.80
Brannigan et al.129 investigated the binding sites of the general anesthetic isoflurane
in the TMD of nAChRs. The nAChR from Torpedo was subjected to computation-based
“flooding” (i.e., simulating a high concentration of anesthetic in the surroundings) of the
receptor and was allowed to partition in the system over the course of an MD simulation
trajectory (Table 3). Their aim was to reduce potential errors that might arise from
homology models.
All the published models mentioned above investigated different aspects of structural
information. Only two models, out of them, were generated to explore the possible
binding site of galantamine (13) and isoflurane in the α7 nAChR ECD and TMD,
respectively, and these are shown in Table 3.126,129
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III. Specific Aims

Within the nAChR family as attractive therapeutic targets for drug discovery,
considerable effort has been aimed toward the identification and development of drugs
that target α7 nAChRs. The binding sites of the endogenous neurotransmitter ACh (i.e.,
orthosteric binding sites) have been the major concern of many drug discovery efforts.
The main objective of research projects targeting orthosteric sites is to identify drugs that
bind to these sites of α7 nAChRs and produce better activation or inhibition of the
endogenous ligand ACh. Nevertheless, one conceivable problem that attenuates the value
of this approach is the difficulty of identifing drugs with adequate subtype-selectivity due
to the high level of sequence homology within the orthosteric binding sites of different
nAChR subtypes.25 The lack of subtype-selective drugs for α7 nAChRs can result in
several undesirable side effects and, thus, limits their clinical use as therapeutic agents.
For example, activation of α4β2 nAChRs can be accompanied by nausea and vomiting,
whereas activation of α3β4 nAChRs at autonomic ganglia and in the CNS is associated
with constipation and weight loss, respectively.130,131 Accordingly, projecting efforts
toward the regulatory binding sites (i.e., the allosteric binding sites) that are at distinct
locations from the highly conserved ACh-binding site (i.e., the orthosteric site) has
!
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gained increasing attention as a promising approach to developing α7 nAChR drugs.
Allosteric binding sites are topologically distinct from the orthosteric binding site and can
represent promising targets for the development of subtype-selective α7 nAChR
drugs.20,25

This dissertation focuses on the discovery and development of small-molecule
arylguanidines that modulate α7 nAChR function with improved subtype-selectivity that
might be achieved through the allosteric approach. Identifying the required structural
features of these small molecules will allow for optimizing their NAM activity at α7
neuronal nAChRs. The two previously synthesized series of compounds identified by our
laboratory, based on MD-354 (20) and its N-methyl analog 24 (Table 2),9 were used as a
starting point to determine the effect of modifications on NAM activity of both series.
Furthermore, the effect of these parallel structural modifications might suggest whether
or not the two series bind at the same allosteric site and, if so, if they bind in a similar
manner (Table 2).9

The present study was aimed toward identifying novel chemical classes of agents that
bind to allosteric binding sites and antagonize α7 nAChR function (i.e., negative
allosteric modulators; NAMs). The primary goals of this research are as follows:

A. QSAR
The identification of the physicochemical properties essential for α7 nAChR NAM
activity is a key approach in current drug discovery and development methods. This step
!
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can be addressed through quantitative structure-activity relationship (QSAR) studies on
closely related analogs possessing the same core structure. QSAR studies are based on
the Hansch assumption of activity–modification of a parent compound by a binding site
that recognizes chemical substituents by specified lipophilic (π), electronic (σ), and other
properties.132

Previous molecular modeling studies at the ECD of α7 nAChRs9 were analyzed using
SYBYL 8.1. Docking of both 20 and 24, performed by the GOLD Suite 5.0 program,
showed plausible binding modes in an allosteric site (characterized by a Thr221) and
revealed two main clusters (Figure 18).9 The rotamers of 20 appeared to utilize the same
binding mode (N1 and N2 form ionic hydrogen bonds with Asp219; hydrophobic
interactions exist between the phenyl ring and Thr221) with alternate locations of the
chloro group (possible hydrophobic interaction with the aliphatic chain of Lys204). In
contrast, N2 and N3 of 24 form ionic hydrogen bonds with Asp219 as the major difference
detected at this allosteric site. N3 shows further a hydrogen bond interaction with Thr221.
The introduction of an N1-methyl group to MD-354 (i.e., 24) appears as the key
difference in activity since the methyl group on N1 precludes ionic hydrogen bonding
with Asp219 (Figure 18).9
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Figure 18. Binding modes of 20 and 24 at the ECD allosteric site (characterized by a

Thr221) of α7 nAChRs as suggested by preliminary molecular modeling studies.9 D =
Asp219.

The two possible binding modes add to the necessity of investigating the structural
requirements for the binding of arylguanidines at α7 nAChRs. The purpose of this study
is to analyze the structural requirements of these compounds that act as NAMs using a
Hansch analysis.132 Analogs of the MD-354 series and the N-methyl series with parallel
structural modifications will be synthesized and investigated. The physicochemical
properties associated with other halogens (i.e., -F, -Br, and -I) in place of the chloro
group will allow for testing mainly the effect of substituent size variation over a relatively
fixed electron-withdrawing nature (Table 4). Replacement of the chloro group with a
-OCH3 or -CH3 group as electron donating groups will explore the effect of such
modifications on activity (Table 4). For the -CF3 group, there is a greater electron
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withdrawing nature than -Cl and other halogens. However, the -CF3 group has a lower
relative electron affinity (EA) than -Cl, a property that provided an explanation for the
lower binding

affinity of -CF3-substituted arylguanidines than -Cl-substituted

arylguanidines to 5-HT3 receptors.133

Table 4. Structural representation of different modifications at the 3-position of the MD354 (i.e., 20) series and the N-methyl (i.e., 24) series of arylguanidines.

NH
HN

NH
H 3C

NH 2

N

X

X

MD-354 (20)
Series

!

NH 2

N-Methyl (24)
Series

Compound

X

Compound

21
20
31
32
33
22
34
23

H
Cl
Br
F
I
CF3
CH3
OCH3

25
24
26
27
28
37
29
30
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Hansch-type QSAR studies will be conducted using several physicochemical
properties such as π (hydrophobic constant), σm (Hammett electronic constant), L
(Verloop length), B1 (Verloop minimum width), B5 (Verloop maximum width), MR
(Molar Refraction), and solvent accessible volume (Vol) (Table 5). This study also
involved application of a widely accepted concept proposed by Portoghese134 in his study
on analgesics, which suggests that “If identically substituted compounds in two different
series are interacting with receptors in a similar manner, then the quantitative
contribution of various substituents to the … effect should produce, under steady-state
conditions, proportionate variations of activity in both series”.
Table 5. Description of various physicochemical parameters.
Parameter

Description

π

Hydrophobic constant132

σm

Hammett electronic constant132

L

Verloop length of the substituent159

B1

Verloop minimum width of the substituent159

B5

Verloop maximum width of the substituent159

MR

Molar refraction160

Vol

Solvent accessibility volumea

NVE

Number of valence electron (Verma et al.)

CMR

Complete molar refractionb

MV

Molar volumec

Pc

Parachor based on surface tension and MVc

Polarizability

Polarizability of the compoundc

a

Calculated by Chimera
Calculated by ChemDraw
c
Calculated by ChemSketch
b
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Hypothesis 1 is that 3-position substituents control the potency of arylguanidines at α7
nAChRs, and that this is related to the physicochemical attributes of these substituents.
This can be evaluated by conducting QSAR studies.
Hypothesis 2 is that arylguanidines and their N-methyl counterparts bind in a dissimilar
manner at α7 nAChRs (as shown in Figure 18). This can be addressed by examining two
related series of compounds to determine if parallel structural changes result in parallel or
non-parallel shifts in NAM potency in accordance with the Portoghese Hypothesis.

B. Topliss Tree

The Topliss Tree approach is a non-mathematical guide for the use of the Hansch
principle.135 The Topliss Tree, usually with the guidance of the Craig Plot,136 allows for
an efficient optimization of the potency of a lead compound with minimal number of
compounds needed to be synthesized. The Topliss operational scheme for the aliphatic
side chain (Figure 19) will be used to optimize pharmacological activities associated with
the alkyl group at the anilinic nitrogen (i.e., N1) of the arylguanidines at α7 nAChRs.
Furthermore, we hope to develop a better understanding of how small-molecule NAMs
interact at α7 nAChRs.
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CH3

i-Pr

H, CH2OCH3,
CH2SO2CH3

Cyclopentyl

C 2H 5

CHCl2, CF3…

Cyclobutyl..

Cyclohexyl..

End

Figure 19. Schematic representation of the Topliss decision-tree for aliphatic side
chain substituents (M, more potent; E, equipotent; L, less potent). Adopted from
Topliss.135

Accordingly, replacement of the N1 methyl group in the N-methyl guanidine series
(i.e., 24, 25) with an isopropyl (i-Pr) group (i.e., 38, 39; Table 6) should increase its π
effect.135 The isopropyl group not only provides more lipophilic character, but also adds
more steric bulk than the methyl group. By examining this structural feature, we can
determine how much bulk can be tolerated by α7 nAChRs for optimal NAM activity. A
total of four pairs of compounds will be examined through which the necessity of the
chloro group will be also investigated with deschloro compounds (Table 6).
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Table 6. Structural representation of proposed compounds with different modifications at
the N1 and 3-position.

Compound

R

X

21

H

H

20

H

Cl

25

CH3

H

24

CH3

Cl

38

CH(CH3)2

H

39

CH(CH3)2

Cl

NH
R

N

NH 2

X

Hypothesis 3 is that application of the Topliss scheme should allow optimization of the
N1 substituent of arylguanidines as α7 nAChR NAMs, if the size and/or lipophilic nature
of the substituent contributes to activity.
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C. Role of the Guanidine Nitrogen Atoms

To gain an understanding of the role of the guanidine nitrogen atoms in the inhibitory
effects of arylguanidines on α7 nACh receptor function, a series of compounds will be
tested (Figure 20). The compounds in this series retain the 3-chlorophenyl moiety,
whereas the differences appear at the guanidine part. With the first compound in this
series, we will test the effect of substitution at a guanidine terminal nitrogen atom (i.e.,
40; Figure 20) on NAM activity. In the remaining compounds of this series, the guanidine
is replaced with modified forms of substructures representing the guanidines missing one
or two nitrogen atoms (i.e., 41, 42, and 43). Our purpose here is to understand the
minimum structural requirement of the guanidine moiety needed for the NAM activity at
α7 nAChRs. In addition, this can provide further insight on the specific molecular
interactions of arylguanidines NAMs at α7 nAChRs.

Hypothesis 4 is that not all of the three guanidine nitrogen atoms (or NH functions) are
required for α7 nAChR NAM actions. This can be examined by investigating compounds
where the NH moiety is replaced by an N-methyl group (i.e., 40), where the NH moiety is
replaced by a methylene group (i.e., 41), or eliminated altogether (i.e., 42). Compound 43
represents an arylguanidine where basic properties have been eliminated (i.e., 43 is an
amide).
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Figure 20. The chemical structures of modified forms of arylguanidines.
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D. Molecular Modeling

1. Homology Modeling and Docking Studies

The primary goal of our molecular modeling studies is to construct and validate a
homology model of the active α7 nAChR. The constructed model will be used to identify
the putative allosteric binding site(s) and to determine the interaction mode(s) of the
studied compounds with α7 nAChRs. Since the α7 nAChR is a homomeric structure, the
molecular modeling of only two attached subunits (i.e., a dimer) is justified, and should
be sufficient to mimic the essential ligand binding domain. The construction will undergo
a number of steps and different software will be employed. Aligning the amino acid
sequence of the targeted portion of the protein with the matching portion of the selected
template amino-acid sequence will be performed using ClustalX 2.0.137 The generation of
multiple models lacking validation will be constructed using Modeller 9.12. Different
docking programs (e.g., GOLD Suite 5.2 and AutoDock 4.2), as well as accurate residue
orientation methods, should allow for model validation by comparing the results with
previously published biochemical or crystallographic data. Therefore, the blind docking
feature of AutoDock 4.2 using Gal (13) and the Connolly surface feature of SYBYL-X
2.1 will be used to explore the possible interaction site(s) at the ECD and the TMD of α7
nAChRs. GOLD Suite 5.2 will be used for model validation through the docking of α7
nAChR agonists (i.e., ACh, nicotine (1), EPI (3)) and the antagonist MLA (9) and
comparing the results with reported crystal structures (PDB ID: 2XZ5, 1UW6, 2BYQ,
and 2BYR, respectively).138-140 Further validation will be performed by docking of α7
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nACh receptor modulators (i.e., Gal (13) for ECD, PNU-120596 (15) and ivermectin (16)
for TMD). Prior to docking of the molecules, we will select the favorable low-energy
conformations that were previously reported as a result of a systematic search
investigation.9 The validated ECD and TMD models of α7 nAChRs will then be used for
the new docking studies after specifying the targeted allosteric cavity. The resulting
complexes of compounds with the candidate ECD and TMD models of α7 nAChRs will
be rescored with the HINT (Hydropathic INTeractions) program,141 an empirical scoring
function based on the experimental free energy information derived from log Po/w (the
solvent partition coefficient for 1-octanol/water). The obtained candidate complexes of
docked compounds at the ECD models of α7 nAChRs will provide beneficial information
that will help in the prediction of required structural modifications to the current series.

2. Crystal Structures of Guanidines

For any bimolecular interaction in biological systems, the existence of specific
attractive forces controls their molecular recognition.125 Sufficient knowledge about the
nature of these specific interactions and their geometries, usually through their crystal
structures, can offer valuable insight for medicinal chemists seeking innovative ways for
drug development.125 When a lead compound has been identified, the optimization
process of its specific attractive interactions becomes a promising approach.
Through reviewing the literature for molecular interactions and analyzing the specific
interactions for a molecule of interest, we hope to reach a deeper understanding of how
guanidines, as a key structural moiety in our series of compounds, might interact with α7
!

64!

!

nAChRs. The approach of optimizing geometry of binding of guanidine compounds with
their protein targets was used, previously, in a number of literature studies for the
development of new guanidine analogs.142,143 As a valued resource for the nature of
molecular interactions, we investigated the PDB database for molecular interactions of
guanidine-containing ligands. We found eight available crystal structures (i.e., PDB IDs:
1S6F, 1S5S, 2VNT, 1ZMJ, 1ZML, 1ZMN, 3PO1, and 3HPT) including guanidinecontaining ligands interacting with different types of serine protease enzymes.144-148
Besides that, identifying these key interactions can be used as references for predicting
the binding mode of our arylguanidine compounds.
Overall, our eventual aim is to rationally design α7 nAChR NAMs with desired
physicochemical and biological properties using multiple medicinal chemistry
approaches.
Hypothesis 5 is that the continual flow of data obtained from different parts in this
project (e.g., biological data and molecular modeling studies) can be integrated using
medicinal chemistry approaches to identify and optimize arylguanidines as NAMs of α7
nAChRs.
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Previous knowledge of the reported allosteric binding sites on α7 nAChRs as well as
α7 nAChR NAMs can also be utilized to provide a rationale for designing novel α7
nAChR NAMs.

The specific aims of the current project are:
a) Determination of the similarity or dissimilarity of the binding modes of the MD-354
series and the N-methyl series of arylguanidines at α7 nAChRs.
b) Identification of what structural features of the 3-position in the arylguanidine
compounds contribute to the activity profile of α7 nAChR NAMs.
c) Optimization of the alkyl substituent at the anilinic nitrogen atom of arylguanidine
NAMs.
d) Investigation of the role of the nitrogen atoms in the guanidine moiety of
arylguanidine compounds for the inhibition profile at α7 nAChRs.
e) Identification of the potential allosteric binding site and the mode of interactions of
arylguanidine NAMs at α7 nAChRs.
f) Identification of a pharmacophore for small-molecule arylguanidine inhibitors for α7
nACh receptor action.
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IV. Results and Discussion

A. Synthesis

The nitrate salt of m-chlorophenylguanidine (MD-354; 20), the hydrochloride salt of
phenylguanidine (PG; 21), the nitrate salt of 3-trifluoromethylphenylguanidine (22), the
hemisulfate salt of 3-methoxyphenylguanidine (23) and the hydrochloride salt of 3methylphenylguanidine (34) were available from previous studies.94,95 The syntheses of
the hydrochloride salt of N-(3-chlorophenyl)-N-methylguanidine (24), the hydrochloride
salt of N-methyl-N-phenylguanidine (25), the hydrochloride salt of N-(3-bromophenyl)N-methylguanidine (26), the hydrochloride salt of N-(3-fluorophenyl)-N-methylguanidine
(27), the hydrochloride salt of N-(3-iodophenyl)-N-methylguanidine (28), the nitrate salt
of N-(3-methylphenyl)-N-methylguanidine (29), and the hydrochloride salt of N-(3methoxyphenyl)-N-methylguanidine (30) were reported in our previous work.9
N-Methyl-3-trifluoromethylaniline nitrate (37) was prepared in three steps according
to a previously published procedure described for similar compounds (Scheme 1).149-151 A
first unsuccessful attempt was made to synthesize the ethyl N-[3-(trifluoromethyl)phenyl]
carbamate (46). In this attempt, ethyl chloroformate was added to a solution of 3-
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trifluoromethylaniline (44) and triethylamine in Et2O and the reaction mixture was heated
at reflux for 1 h resulting in a major product of urea derivative 45 (i.e., dimeric product).
An alternative condition to obtain the desired intermediate carbamate 46 was used; ethyl
chloroformate was added in a dropwise-manner to a solution of 3-trifluoromethylaniline
(44) and sodium hydride to yield the desired carbamate in 88% yield. The carbamate 46
was then reduced to N-methyl-3-trifluoromethylaniline using LiAlH4 in THF and the HCl
salt 47 was prepared. An ethanolic solution of 47 was heated at reflux with cyanamide to
give 37. The structure of the compound was confirmed by IR, 1H NMR, and elemental
analysis for C, H, N.

Scheme 1.a
O
HN

NH 2

a

CF 3

NH

CF 3

F 3C

44

45
O

b
HN

CH 3
O

H 3C

c,d

NH
NH

e,f

H 3C

N

HCl

CF 3

a

HNO3

CF 3

46

47

NH 2

37

CF 3

Reagents and conditions: a. ethyl chloroformate, Et3N, Et2O, reflux; b. ethyl

chloroformate, NaH, THF, reflux; c. LiAlH4, THF, reflux; d. HCl/Et2O; e. NH2CN,
absolute EtOH, reflux; f. NH4NO3, H2O.
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Scheme 2 describes the synthesis of N-isopropyl-N-phenylguanidine nitrate (38). The
synthesis consisted of a one-step reaction according to a literature procedure for a similar
compound.152 Cyanamide was reacted with N-isopropylaniline hydrochloride (48) in
EtOH.

The

hydrochloride

salt

of

N-(3-methylphenyl)-N-methylguanidine

was

hygroscopic and, because of that, was converted to the nitrate salt using ammonium
nitrate. The structure of N-isopropyl-N-phenylguanidine nitrate (38) was confirmed by
IR, 1H NMR, and elemental analysis for C, H, N.

Scheme 2.a

CH 3
H 3C

CH 3 NH

NH
HCl

H 3C

a

NH 2
HNO3

48

a

N

38

Reagents and conditions: a. i) NH2CN (50% aqueous), EtOH, reflux; ii) NH4NO3, H2O.

N-(3-Chlorophenyl)-N-isopropylguanidine hydrochloride (39) was prepared as
described in Scheme 3. This was an unknown compound at the time of synthesis, but was
prepared according to a literature procedure for a similar compound.151,153 3Chloroaniline (49) was treated with 2-bromopropane (50) in the presence of an aqueous
solution of NaOH, allowing for a nucleophilic substitution reaction to yield the 3-chloro-
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N-isopropylaniline (51). The final step was performed by heating an ethanolic solution of
the hydrochloride salt of 51 at reflux with cyanamide to give 39. The desired compound
was confirmed by IR spectrometry, 1H NMR spectrometry, and elemental analysis for C,
H, N.

Scheme 3.a!
CH3

NH 2

Br
H 3C CH 3

a,b

H 3C

NH
HCl

Cl

49

a

CH 3 NH

c

H 3C

N

Cl

50

51

NH 2

HCl

Cl

39

Reagents and conditions: a. NaOH (15% aqueous), ZnCl2 (saturated aqueous), 150 °C;

b. HCl/Et2O; c. NH2CN, EtOH, reflux.

Based on the initial biological results obtained for compounds 38 and 39, compounds
52 and 53 were synthesized (see discussion below). N-Ethyl-N-phenylguanidine
hydrochloride (52) was synthesized according to a literature procedure in a one-step
reaction as described in Scheme 4.154 The N-ethylaniline hydrochloride (54) was allowed
to react with a cyanamide in 1-pentanol. The desired product obtained was confirmed by
IR, 1H NMR, and melting point.
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Scheme 4.a

CH 3
NH

CH 3 NH
HCl

a

54

a

N

NH 2

HCl

52

Reagents and conditions: a. NH2CN, 1-pentanol, reflux.

Scheme 5 summarizes the synthesis of N-(3-chlorophenyl)-N-ethylguanidine
hydrochloride (53). This was an unknown compound at the time of synthesis, but was
prepared according to a literature procedure for a similar compound.151,155 3Chloroaniline (49) was alkylated through a reductive amination step using acetaldehyde
and pyridine-borane to yield 3-chloro-N-ethylaniline (55). The final step was performed
by heating the ethanolic solution of the hydrochloride salt (i.e., 55) at reflux with
cyanamide to give 53. The desired compound was confirmed by IR spectrometry, 1H
NMR spectrometry, and elemental analysis for C, H, N.
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Scheme 5.a

CH 3 NH

CH 3

NH 2

NH HCl

a,b

N

c

NH 2

HCl

Cl

Cl

Cl

49

a

55

53

Reagents and conditions: a. acetaldehyde, pyridine-borane, MeOH, reflux; b. HCl/Et2O;

c. NH2CN, EtOH, reflux.

Three additional compounds (i.e., 56-58), suggested by the obtained results (see
discussion below), were synthesized. N-(3-Cyanophenyl)-N-methylguanidine nitrate (56)
was synthesized according to a literature procedure for a similar compound in a one-step
reaction as described in Scheme 6.154 3-(Methylamino)benzonitrile hydrochloride (59)
was allowed to react with cyanamide in ethanol. The desired product obtained was
confirmed by IR, 1H NMR, MS, and elemental analysis for C, H, N.
Scheme 6.a
H 3C

NH
NH
HCl

a

H 3C

N

NH 2
HNO3

CN

CN

59

a

!

56

Reagents and conditions: a. NH2CN, EtOH, reflux.
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Scheme

7

summarizes

the

synthesis

of

N-cyclopentyl-N-phenylguanidine

hydrochloride (57) and N-(3-chlorophenyl)-N-cyclopentylguanidine nitrate (58). The first
step in the synthesis of these two unknown compounds was a reductive amination
reaction of aniline (60) and 3-chloroaniline (49), respectively, and cyclopentanone (61) in
the presence of sodium triacetoxyborohydride (STAB). The hydrochloride salts of the
obtained compound (i.e., 62 and 63, respectively) were then heated at reflux with
cyanamide to give 57 and 58 (the former as its hydrochloride salt). An additional step
was performed to convert the hygroscopic 58 hydrochloride salt to the nitrate salt using
ammonium nitrate.
! Scheme 7.a

NH
O

NH 2

NH

a,b

HCl

X

X = H; 60
X = Cl; 49

N

c

NH 2
HCl

X

61

X = H; 62

c,d

57

X = Cl; 63

NH
N

NH 2
HNO3

Cl

58

a

Reagents and conditions: a. STAB, acetic acid, DCM, room temperature; b. HCl/Et2O; c.

NH2CN, EtOH, reflux; d. NH4NO3, H2O.
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B. Biological Data

Our previous findings9 for investigating and optimizing the inhibitory effect of the
arylguanidines were obtained using the whole-cell configuration of the patch-clamp
technique on rat α7 nAChRs expressed in stably transfected human embryonic kidney
(HEK) 293 cells. The number of compounds tested were neither sufficient to identify the
key physicochemical property for interaction with α7 nAChRs nor enough to decide if the
N-methyl series binds in a similar or dissimilar manner at α7 nAChRs as MD-354 series.9
The functional data in the current project were obtained by evaluating the biological
potencies of the compounds in inhibiting ACh-induced responses in Xenopus laevis
oocytes expressing human α7 nAChRs using an automated two-electrode voltage-clamp
assay. Here, the automated system was introduced to overcome several drawbacks
associated with conventional patch-clamping techniques such as time-consuming issues
and being very laborious.156 However, recorded potencies of our compounds are expected
to be lower compared to those from the previously used HEK 293 cells because oocyte
surface components, such as the large number of invaginations in the membrane and the
surrounding vitelline membrane and follicle cells, decrease the accessibility of the
compounds.157 All inhibitory effects measured here were reported in the form of halfmaximal inhibitory concentrations (i.e., IC50 values). Compounds 20-34, 37 and 38
showed inhibitory action (Table 7) and potency varied over a 10-fold range.
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Table 7. IC50 values for α7 nAChRs of different structural modifications at the 3-position
of the MD-354 series and the N-methyl series of arylguanidines.
!
!

NH

!
!

HN

!

NH
H3C

NH2

N

NH2

X

X

!

MD-354 (20)
Series

!

!

N-Methyl (24)
Series

!

!

!

!

!

IC50 ± SEM (µM)

Compound

X

Compound

IC50 ± SEM (µM)

_59.75 ± 1.21

21

H

25

125.40 ± 1.12

_41.51 ± 1.24

20

Cl

24

_31.45 ± 1.40

_23.58 ± 1.08

31

Br

26

_30.23 ± 1.27

_53.60 ± 6.69

32

F

27

_73.22 ± 1.41

_21.81 ± 1.24

33

I

28

_12.63 ± 1.41

_21.29 ± 1.21

22

CF3

37

_31.04 ± 2.82

118.40 ± 1.97

34

CH3

29

_31.41 ± 1.30

_40.00 ± 1.44

23

OCH3

30

_57.09 ± 1.98
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1. QSAR

The chloro group at the 3-position of both MD-354 (20) and 24 was replaced with a
number of substituents considering the electronic, the lipophilic, and the steric nature of
the new substituent (Table 7). The introduction of other halogen atoms (i.e., -F, -Br, and
–I) at the 3-position allowed for testing mainly the effect of substituent-size variation
over a relatively fixed range of electron-withdrawing effects. Furthermore, replacement
of the chloro group with -CH3 or -OCH3 groups as electron-donating groups explored the
effect of such modification on activity. By examining the inhibitory activity of these two
series of arylguanidine analogs (n = 16) at α7 nACh receptors, we hoped to answer
multiple questions regarding binding modes of arylguanidines and the impact of parallel
substituent modifications at the aryl 3-position. The obtained IC50 values showed a range
of 21 – 118 µM and 12 – 125 µM, respectively (Table 7). Plots for representative
compounds of these two series (i.e., MD-354 (20) and its N-methyl analog (24)) are
shown in Figure 21; IC50 of 41.51 ± 1.24 µM and 31.45 ± 1.40 µM, respectively were
calculated. While removing the chloro group of MD-354 (20) caused a slight reduction in
potency (i.e., 21, IC50 = 59.75 µM; compared to MD-354 (20), IC50 = 41.51 µM), a more
pronounced effect of chloro group removal (more than four-fold reduction in potency)
was seen in the N-methyl series (i.e., 25, IC50 = 125.40 µM; compared to 24, IC50 = 31.45
µM). Furthermore, the least potent inhibitor in the MD-354 series was the 3-methyl
analog 34 (IC50 = 118.40 µM) whereas the least potent in the N-methyl series is the
deschloro analog 25 (IC50 = 125.40 µM). Detailed graphs representing functional data of
these compounds are shown in Appendix A.

!

76!

!

!

!

[24] (M)
Figure 21. Concentration/response curves for MD-354 (20) and its N-methyl analog
(24) (n = 4) inhibition of peak currents elicited by 100 µM ACh at α7 nAChRs.

To determine if the two series bind in similar manner, we investigated the impact of
parallel substituent modifications at the aryl 3-position in the two series of analogs. That
is, if the two series are binding in a common manner, there should be a relationship
between their potencies. That is, it would be expected that their potencies would co-vary.
Linear regressions and statistical analyses implemented in this project were conducted
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using GraphPad Prism® software (version 5.04),158 SPSS (Statistical Package for the
Social Sciences; version 22.0), and JMP (John’s Macintosh Program; version 11.2).
Correlations expressing a p value of less than 0.05 were considered significant. A poor
correlation (r = 0.474; n = 8) was found between pIC50 values of the MD-354 (i.e., NH)
series versus pIC50 values of the N-methyl series (Figure 22). Data on the 3-CH3 analog
of the N-methyl series (i.e., 29) were replicated and no difference was observed in the
IC50 value. Follow-up statistical analysis was conducted to detect any potential outliers
among the obtained inhibitory potency values using Cook’s D, and Z score methods,
specifically for the 3-CH3 compounds (Table 8). All IC50 values of the tested compounds,
including the 3-CH3 analogs, appeared to be within the acceptable range and no single
value exceeded the cutoffs. Therefore, it is unlikely that the two series are interacting in
the same manner at α7 nAChRs. This finding supported our previously proposed binding

N-Methyl series pIC50

modes identified by preliminary docking studies (i.e., as shown in Figure 18).

I
CH3

Cl

CF3

OCH3

!

F
H

Br

!

MD-354 series pIC50

Figure 22. Plot of pIC50 values of the MD-354 (20) series versus the N-methyl analog
series (r = 0.474, p = 0.235, n = 8).
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Table 8. Outlier detection tests and the calculated cut-off values.

Test

Calculated Range

Cut-off

Software

Cook’s D

0.00092 – 0.4128

> 0.5

SPSSa

Zscore

-1.6549 – 1.6459

± 2.5

SPSSa

Cook’s Influence

0.0182 – 0.4471

>1

JMPb

a

The Statistical Package for the Social Sciences (SPSS Science, Chicago, IL).

b

John’s Macintosh Program (JMP, SAS Institute Inc., Belmont, Canada).

To analyze the influence of structural features at the 3-position of these compounds to
act as inhibitors at α7 nACh receptors, Hansch-type QSAR studies were performed
examining several physicochemical properties of the substituent at the 3-position; π
(hydrophobic constant),132 σm (Hammett electronic constant),132 Verloop’s steric
parameters (L, Verloop length; B1, Verloop minimum width; B5, Verloop maximum
width),159 MR (Molar refraction),160 and solvent accessibility volume (Vol) as calculated
using Chimera 1.10.1,161 Number of valence electron (NVE),162 Complete molar
refraction (CMR) as calculated using ChemBioDraw (version 13.0), Molar Volume
(MV), Parachor value (Pc) as calculated using ChemSketch (version 10.0), and
polarizability.162 Detailed numerical values of all these physicochemical parameters for
the currently used substituents are shown in Table 9. Data showed that the action of the
MD-354 series seemed to be positively correlated with the electronic character (σm) of
their meta substituent (r = 0.820; n = 8) (Figure 23) and no other correlations were found
(Table 10). However, the narrow range of IC50 values in this series indicated a need to
consider additional
!

compounds.
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Table 9. Hansch-type QSAR analysis of the α7 nAChR inhibitory activity of 3-substituted arylguanidines.!
NH

NH
H

N

H 3C

NH 2

N

X

X

X

IC50 (µM)a

πb

σmb

L

H

_59.75 ± 1.21

0

0

2.06

1

1

0

122

52

4.08

115

304

Cl

_41.51 ± 1.24

0.14

0.34

2.65

1.35

1.35

0.92

126

58

4.1

118

Br

_23.58 ± 1.08

0.71

0.37

3.52

1.8

1.8

6.03

145

58

4.57

F

_53.60 ± 6.69

0.86

0.39

3.82

1.95

1.95

8.88

166

58

I

_21.81 ± 1.24

1.12

0.35

4.23

2.15

2.15

13.94

198

CF3

_21.29 ± 1.21

0.88

0.43

3.3

1.98

2.61

5.02

CH3

118.40 ± 1.97

-0.02

0.12

3.98

1.35

3.07

OCH3

_40.00 ± 1.44

0.56

-0.07

2.87

1.52

2.04

b

B1

b

a

IC50 data from Table 7.

b

See Table 5 for the description of parameters.

!

NH 2

B5

b

b

b

b

b

b

b

b

IC50 (µM)a

X

15.51

125.40 ± 1.12

H

304

15.46

_31.45 ± 1.40

Cl

124

333

17.33

_30.23 ± 1.27

Br

4.86

127

347

18.51

_73.22 ± 1.41

F

58

5.39

132

367

20.53

_12.63 ± 1.41

I

151

76

4.59

145

358

17.39

_31.04 ± 2.82

CF3

7.87

146

64

4.7

137

354

17.81

_31.41 ± 1.30

CH3

5.65

138

58

4.54

130

335

17.26

_57.09 ± 1.98

OCH3

MR

Vol

80!

NVE

CMR

MV

Pc

Polariz.

Table 10. Summary of the linear regression analysis results for MD-354 series (n = 8).
Equation
No.

QSAR Equation for pIC50

r

F

p

1

0.9700 (± 0.5705) π -3.732 (± 2.511)

0.570

2.89

0.140

2

0.6194 (± 0.1763) σm -2.481 (± 0.7762)

0.820

12.34

0.012

3

1.851 (± 0.8862) L -4.830 (± 3.901)

0.648

4.36

0.081

4

1.075 (± 0.4440) B1 -3.088 (± 1.954)

0.703

5.86

0.052

5

0.9364 (± 0.9639) B5 -2.119 (± 4.243)

0.368

0.94

0.369

6

9.317 (± 5.899) MR -34.91 (± 25.97)

0.541

2.49

0.165

7

64.89 (± 27.64) Vol -136.2 (± 121.7)

0.691

5.51

0.057

8

12.93 (± 9.965) NVE +3.413 (± 43.86)

0.468

1.68

0.242

9

0.9616 (± 0.5335) CMR +0.3771 (± 2.348)

0.592

3.25

0.121

10

17.49 (± 13.79) MV +51.62 (± 60.69)

0.459

1.61

0.252

11

57.77 (± 29.11) Pc +83.82 (± 128.1)

0.629

3.94

0.094

12

3.694 (± 2.085) Polarizability +1.238 (± 9.178)

0.586

3.14

0.127

σm

F

H
CH3

Cl

Br

CF3
I

OCH3

MD-354 series pIC50

Figure 23. Plot of pIC50 values of the MD-354 (20) series versus the electronic
character (σm) (r = 0.821, p = 0.012, n = 8).
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On the other hand, a significant positive correlation was found between pIC50 values of the
N-methyl series compounds with their lipophilic nature (π) (r = 0.912; n = 8) and their minimum
width (Verloop B1) (r = 0.927; n = 8) (Figure 24A and B, respectively) (Table 11). These two
parameters gave the best-fitting models that are supported by the highest F values (Table 11).
This suggests the importance of these physicochemical properties at the 3-position of the Nmethyl series. However, a significant internal correlation exists between the two properties (r =
0.956; n = 8) (Figure 25). Detailed correlation plots of all these physicochemical parameters for
the currently used substituents in the N-methyl series are shown in Appendix B.

Table 11. Summary of the linear regression analysis results for N-methyl (i.e., 24) series (n = 8).
Equation

QSAR Equation for pIC50

r

F

p

13

1.326 (± 0.2431) π -5.303 (± 1.072)

0.912

29.74

0.001

14

0.2923 (± 0.2348) σm -1.045 (± 1.035)

0.453

1.55

0.260

15

1.860 (± 0.6427) L -4.883 (± 2.835)

0.763

8.38

0.030

16

1.211 (± 0.2000) B1 -3.693 (± 0.8819)

0.927

36.68

0.001

17

0.9730 (± 0.7918) B5 -2.286 (± 3.492)

0.448

1.51

0.265

18

12.85 (± 2.902) MR -50.53 (± 12.80)

0.875

18.61

0.021

19

70.71 (± 15.37) Vol -162.2 (± 67.81)

0.882

12.16

0.013

20

6.216 (± 9.293) NVE +32.89 (± 40.99)

0.263

0.44

0.528

21

1.238 (± 0.2545) CMR -0.8450 (± 1.123)

0.893

3.24

0.122

22

17.57 (± 11.16) MV +51.17 (± 49.21)

0.540

2.48

0.166

23

63.14 (± 18.97) Pc +59.83 (± 83.65)

0.805

11.08

0.023

24

4.794 (± 1.001) Polarizability -3.625 (± 4.416)

0.890

9.87

0.016

No.
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A

B1

CF3 Br
Cl
F

I

CH3

OCH3

H

N-Methyl series pIC50
B

π

CF3 Br
Cl
CH3
H

I

F
OCH3
N-Methyl series pIC50

Figure 24. Plot of pIC50 values of the N-methyl series versus A) the Verloop minimum
width (B1) (r = 0.927, p = 0.001, n = 8) and B) the hydrophobic constant π (r = 0.912, p
= 0.001, n = 8).
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B1

!

OCH3

Cl
F

CF3
Br

I

CH3

H

π
Figure 25. Plot describing the internal correlation between the hydrophobic
constant (π) and Verloop minimum width (B1) (r = 0.956, p = 0.0016, n = 8).

Based on the above QSAR studies, there appears to be dissimilar binding modes for the two
series of compounds at α7 nAChRs (i.e., structure-activity results for one series cannot be
applied to the other). Among the examined physicochemical properties, only electronic character
appeared to play a role at the 3-position of the MD-354 series for α7 nAChR action; however,
more compounds are required to substantiate this. For the N-methyl series, two major factors
appear to be involved as important structural features at that position for α7 nAChR action (i.e.,
lipophilic nature and the minimum width of the substituent). Due to a significant intercorrelation
between the two parameters examined for the current data set (i.e., between π and Verloop B1), it
was not possible to identify a single parameter as being the more important. Consequently, it was
of interest to synthesize an additional compound in this series that clarifies uncertainty associated
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with the importance between these two parameters. Thus, the next candidate compound to be
synthesized and tested was the 3-CN analog (56) since it provides a high Verloop minimum
width value (B1 = 1.6) and low lipophilic character (π = -0.57). According to Equation 13
(Table 11), if the hydrophobic character is the most important physicochemical property, the IC50
value will be 0.873 µM. Whereas, if the minimum width property is the most important
physicochemical parameter, the IC50 value, according to Equation 16, will be 17,563 µM.
From this point, our efforts will only consider the N-methyl series for further investigation.
The MD-354 series is not of particular interest due to selectivity reasons since these compounds
bind reasonably well at 5-HT3 receptors.

2. Topliss Tree

The above QSAR analysis of the N-methyl series of aryl guanidines focused on investigating
the effects of various substituents at the aryl 3-position. The Topliss-decision tree approach
allows an investigation of the lipophilic effect at the N1 position. The necessity of introducing the
N-isopropyl pairs was also to test whether or not the two series of compounds (i.e., the chloro
and the deschloro compounds) interact with α7 nACh receptors in a similar manner depending
on the fold-difference in biological data obtained. The examination of inhibitory action of a fixed
concentration (i.e., 10 µM) of compounds 20, 21, 24, 25, 38, and 39 at α7 nACh receptors
resulted in a different extent of inhibition compared to the normalized current evoked by ACh at
its EC50 concentration (Figure 26). Incorporation of the N-isopropyl group as seen in 39 not only
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increases lipophilicity but adds extra steric bulk that appears to be not as well tolerated as the Nmethyl group in 24. Results also showed that the introduction of an isopropyl group in 38 seems
to result in retention of inhibition potency at α7 nAChRs. The new isopropyl analogs appear to
have less selectivity and can inhibit α3β4 nAChRs, especially the 3-chloro compound 39 (Figure
26). Furthermore, it seems that there is a non-parallel inhibitory effect between the chlorodeschloro pairs of compounds indicating either possible different binding modes or distinct
binding sites for the two series. This suggests that the introduction of an ethyl group (i.e., 52, and
53 for the deschloro and chloro analogs, respectively) might optimize the effect, especially for
the chloro series (20, 24, and 39).
NH
H

N

NH 2

NH
H

N

Cl

NH 2

NH
H 3C

1

N

NH 2

CH 3 NH

NH

Cl

H 3C

N

H 3C

NH 2

N

NH 2

CH 3 NH
H 3C

N

NH 2

0.5

Cl

0

ACh
ACh

120

21
2

24
3

25
4

39
5

38
6

Figure 26. Effect ± SEM of 20, 21, 24, 25, 38, and 39 at 10 µM concentration on ACh
function at α7 (ACh EC50 = 280 µM; red bars) and α3β4 (ACh EC50 = 100 µM; blue
bars) nAChRs relative to ACh (normalized current = 1).
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The IC50 values obtained later showed different inhibition patterns of these compounds on α7
nAChR function (Table 12). Replacing the methyl group in 24 with isopropyl (i.e., 39) caused a
slight improvement in potency. Removing the chloro group of 39 (i.e., 38) caused no effect on
potency (Table 12). The most dramatic effect of chloro group removal (more than four-fold
reduction in potency) was seen in the N-methyl series (i.e., 25, IC50 = 125.40 µM; compared to
24, IC50 = 31.45 µM). Furthermore, although it is perhaps premature to draw definitive
conclusions, when comparing antagonist potency of the two pair of compounds 20, 21 in the
guanidine series and 24, 25 in the N-methyl series, the data suggest that the two series of
compounds might bind in a different manner because parallel structural modifications did not
result in a parallel shift in activity (Figure 26). That is, removal of the 3-Cl group in the
guanidine series resulted in a ca. 5-fold decreased potency whereas in the N-methyl series it was
ca. 25-fold. If the compounds were binding in the same manner, the shift in activity might be
expected to be of the same magnitude. However, additional compounds are needed to support
such an assumption and the next candidate compounds, according to Topliss tree approach, are
the deschloro and the 3-chloro analogs of N-cyclopentyl-N-phenylguanidine (i.e., 57 and 58,
respectively).163
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Table 12. IC50 values at α7 nAChRs for arylguanidines with different structural modifications at
the N1 and 3-positions.

NH
R

N

NH 2

X

Compound

R

X

IC50 ± SEM µM

21

H

H

59.75 ± 1.21

20

H

Cl

41.51 ± 1.24

25

CH3

H

125.40 ± 1.12

24

CH3

Cl

31.45 ± 1.40

52

C 2H 5

H

39.84 ± 1.07

53

C 2H 5

Cl

26.92 ± 1.07

38

CH(CH3)2

H

19.78 ± 1.35

39

CH(CH3)2

Cl

21.89 ± 1.42

3. Role of Nitrogen Atoms

The purpose here was to develop an understanding of the role of the guanidine moiety in
arylguanidine inhibitory actions at α7 nAChRs. We investigated the effect of alkylating one or
more of the guanidine nitrogen atoms, and the necessity of the presence of these nitrogen atoms
in our compounds for their inhibitory action. With respect to the arylguanidines, it is already
known that the introduction of a methyl group at the aniline nitrogen of MD-354 (20) (i.e., 24)
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improved both potency and selectivity at α7 nAChRs. The incorporation of a methyl group at the
terminal nitrogen atom (i.e., 40; IC50 = 22.07 µM) resulted in a slight improvement in potency
compared to MD-354 (20, IC50 = 41.51 µM); however, this modification is detrimental to the
inhibition efficacy since the dose-response curve does not show a complete inhibition of the ACh
response at high concentrations (Figure 27A). Furthermore, replacement of the aniline NH by a
methylene group (i.e., 41), or removing one of the terminal nitrogen atoms of 41 (i.e., 3chlorophenylethylamine; 42) resulted in retention of potency relative to MD-354 (20),
respectively, at α7 nACh receptors (Figure 27B and C). The replacement of one of the two
terminal nitrogen atoms with a carbonyl oxygen atom (i.e., 3-chlorophenylurea; 43; EC50 = 365.9
µM) resulted in an activator molecule for α7 nAChRs (Figure 27D).
From the tested compounds reported in the above data, it would seem that not all of the
nitrogen atoms are required for activity at α7 nAChRs. This observation, however, requires
further testing to determine the mechanism of inhibition (i.e., competitive or non-competitive
inhibition) and the mode of binding of these compounds at the molecular level. That is, these
provide multiple means to block the actions of ACh. These analogs might produce their action by
binding at the orthosteric site, a different allosteric site (other than that to be described in the next
section) and/or as channel blockers. However, these findings open new avenues for future
investigation.

! 89!
!

!
!

A

!
IC50 = 22.07%±%1.29
NH
HN

N
H

CH3

Cl

[40]

B

C

!

!
IC50%= 23.89%±%1.56

IC50 = 32.12%±%1.60

NH

NH 2

NH 2

Cl

Cl

[41]

D

[42]

O
HN

EC50%=%365.9%±%7.5%
!

NH 2

Cl

[43]

Figure 27. Plot of IC50 curves for 40 (A), 41 (B), and 42 (C) in µM at α7 nAChRs (ACh
concentration is 100 µM). Compound 43 (D) showed weak agonist activity at α7
nAChRs.
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C. Molecular Modeling

1. Sequence Alignment and Homology Modeling
Homology modeling studies were used to address a number of questions regarding the
potential binding site(s) and the mode of interactions that explain the functional activity of our
compounds at α7 nAChRs. All primary sequences used in our alignment were obtained from the
Universal Protein Knowledgebase (UniProtKB). Multiple alignments of the human α7 nAChR
sequence with several orthologs were performed using ClustalX 2.0 and key amino acid residues
were determined (Figure 28 and 29). Furthermore, these alignments were established to identify
and match conserved residues between the human α7 nAChR and the template, the X-ray crystal
structure of a chimeric ECD of a human α7 nAChR and an Lymnaea stagnalis acetylcholine
binding protein (AChBP) (PDB ID 3SQ6) that shares 64% sequence identity with the ECD of the
human α7 nAChR ECD, the NMR structure of the TMD of the α4 nAChR subunit (PDB ID
2LLY) that shares 49% sequence identity with the TMD of the human α7 nAChR, and the cryoelectron microscopy structure of Torpedo marmorata nAChR (PDB ID 2BG9) that shares 53%
sequence identity with the TMD of the human α7 nAChR.
Through aligning the primary sequence of the ECD of the human α7 nAChR with the
template, important regions in the aligned sequences were identified including the loops A, B, C,
D, E, and F that primarily formed the orthosteric binding sites in these receptors (Figure 28).
Furthermore, the two cysteine residues (i.e., Cys150 and Cys164) forming the disulfide bond
characterizing the Cys-loop, and the adjacent two cysteine residues (Cys212 and Cys213)
forming the disulfide bond at the C loop were also matched. The advantage of using the primary
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sequence of the chimeric ECD of the α7 nAChR (PDB ID 3SQ6) can be seen through the
presence of many amino acids that are highly conserved with the human α7 nAChR sequence.
Other important amino acids are Val220, Thr221, and Phe222 that are known to interact with α7
nAChR PAM galantamine (13).70
D

hα7
3SQ6
A

E

hα7
3SQ6
F

B

hα7
3SQ6
C

hα7
3SQ6

Figure 28. Sequence alignment of the ECD portion from the human α7 nAChR and α7
nAChR chimera. The asterisks (*) indicate conserved amino acids, whereas the colons
(:) and periods (.) indicate strongly and weakly conserved amino acids, respectively. The
colored lines represent the main loops in the ECD. The red box indicates the galantamine
binding site as shown by Ludwig et al.70
Sequence alignments of the TMDs of the α7 nAChRs and the templates used revealed a low
degree of similarity compared to the ECDs alignments. Important regions in the aligned
sequences were identified which included Glu237 and Glu258 at the ends of M2, the amino acids
responsible in forming the upper and lower rings within the pore of the α7 nAChR (Figure 29).25
Other identified residues include Ser222 and Ala225 from M1, Met253 from M2, Gln272 from
M3, and Phe455, Thr456 and Cys459 from M4 that are known to have essential interactions with
two α7 nAChR PAMs, PNU-120596 (15) and ivermectin (16).80
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M2

M1

hα7
2LLY
2BG9
M3

hα7
2LLY
2BG9

hα7
2LLY
2BG9

hα7
2LLY
2BG9
M4

hα7
2LLY
2BG9

Figure 29. Sequence alignment of the TMD portion of nAChRs from three species. The
asterisks (*) indicate conserved amino acids, whereas the colons (:) and periods (.)
indicate strongly and weakly conserved amino acids, respectively. The four main TMDs
are represented by the turquoise lines. The red box indicates important amino acid
residues interacting with either PNU-120596 or ivermectin as shown in Young et al.74
Construction of 100 homology models was accomplished in the form of dimers of the human
α7 nAChR ECD and in the form of monomers of the TMD using Modeller 9.12. Dimer
formation provided the essential part of the ECD for the molecular modeling study since α7
nACh receptors are homomeric and the orthosteric binding site is located between each two
subunits. The three-dimensional structures of 100 models of each domain were energetically
evaluated based on DOPE (Discrete Optimized Protein Energy) scores. A subsequent validation
step was performed by the docking of α7 nACh receptor modulators (i.e., galantamine (13) for
the ECD, and PNU-120596 (15) and ivermectin (16) for the TMD).
! 93!
!

!
!

2. Crystal Structures of Guanidines

In the PDB archive, we found that guanidine-containing ligands have common patterns in
their interactions with macromolecules. The protonated form of guanidines (i.e., the guanidinium
group) is the common form at physiological pH, which suggests their potential involvement in
electrostatic interactions.144,145 In most cases, guanidinium groups were found to form bidentate
interaction with the side-chain carboxylate of aspartate amino acids (i.e., 1 and 3-5; Table 13).144146

The orientation of the guanidine-containing ligands, in some cases, restricted the bidentate

form, so that only one ionic hydrogen bond instead of two was formed with the side-chain
carboxylate of aspartate and glutamate amino acids (i.e., 2, 6, and 7; Table 13).146 Guanidinium
groups, also, are able to form hydrogen bonds with the side-chain hydroxyl groups of serine
residues (i.e., 1-3; Table 13) and with the backbone oxygen atoms of amino acids (i.e., 1-6, and
8; Table 13).144-148
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Table 13. Summary of interactions of guanidinium groups in guanidine-containing ligands from
the PDB database.
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3. Allosteric Binding Site Exploration

Eight putative allosteric binding pockets for the small-molecule NAMs of α7 nAChRs were
initially identified, through cavity-search studies conducted with the Connolly surface feature of
SYBYL-X 2.1 and the blind docking feature of AutoDock 4.2 at the α7 nAChR model. Initial
findings indicated the presence of five cavities at the ECD and three cavities at the TMD (I-VIII;
Figure 30). The five cavities found in the ECD are in agreement with the previously reported
work of Iorga et al.126 (ECD upper exterior site (I), the orthosteric site (II), ECD-lower exterior
site (III), ECD-upper interior site (IV), and ECD-lower interior site (V); Figure 30A and B).
Further evaluation of these potential binding pockets was performed to exclude cavities that
violate logical standards. Prior knowledge that both MD-354 (20) and 24 are not competitive
antagonists and not channel blockers led to the elimination of three cavities (i.e., the orthosteric
site (II), ECD-upper interior site (IV), and ECD-lower interior site (V)). Also, the ECD-upper
exterior site was eliminated from consideration due to limited cavity volume (i.e., 123 Å3
compared to 145 Å3 and 161 Å3, the molecular volume for 20 and 24, respectively). This
suggested that the ECD-lower exterior site is the only ECD site candidate for our modeling and
docking studies.
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Figure 30. A and B represent side views of the modeled ECD of the human α7 nAChR
dimer showing the location of allosteric cavities I-V at the exterior and interior surfaces,
respectively. C represents top view of the TMD showing the location of allosteric
cavities VI-VIII.
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Similarly, the three TMD cavities (i.e., TMD intrasubunit site (VI), TMD exterior site (VII),
TMD interior site (VIII); Figure 30C) were analyzed. These cavities were in agreement with
reported computational work of Brannigan et al.129 on possible binding pockets of the anesthetic
isoflurane in nicotinic receptors. Both the TMD exterior site and TMD interior site were
eliminated due to limited cavity volume (i.e., 116 Å3) and the channel blocking problem,
respectively. This makes the TMD intrasubunit site the most likely TMD site candidate for our
modeling and docking studies.
The two identified binding pockets (i.e., the ECD-lower exterior site (III) and the large TMD
intrasubunit cavity (VI)) are known to be the binding site for α7 nAChR modulators. For
example, galantamine (13) is an α7 nAChR PAM that interacts at the ECD-lower exterior site
(III), whereas ivermectin and PNU-120596 are two α7 nAChR PAMs that interact in distinct
locations at the general TMD intrasubunit cavity. This fact led us to target three different
locations; one at the ECD characterized by amino acid residue Thr221 and two in the TMD
intrasubunit cavity that are characterized by amino acid residues Met253 (i.e., the key amino acid
for ivermectin binding) and Ser222 (i.e., the key amino acid for PNU-120596 binding). All these
key residues were determined using the reported mutagenesis data70,74 that were discussed above.

4. Docking Studies and Hydropathic Analyses

Within SYBYL-X 2.1, four low-energy rotamers of arylguanidine analogs were
computationally prepared for docking. Molecular docking was conducted using the CHEMPLP
scoring function (within the genetic algorithm docking program GOLD 5.2) and the docking
solutions were analyzed (SYBYL-X 2.1). The binding site was defined to include all atoms
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within 10 Å of the α-carbon atom of the key amino acid residue for the candidate homology
models. Based on the fitness scores and the binding orientation of each ligand within the binding
cavity, the best-docked solution was selected and merged into the receptor. Energy minimization
was carried out using the Tripos Force Field to optimize the interactions between ligand and
receptor within the binding pocket, followed by PROCHECK and ProTable analyses to validate
the candidate models.
The optimized model-ligand complexes were then rescored with the HINT program (Table
14) in order to compare and contrast different binding pockets. Further evaluation of HINT
scores was performed using Boltzmann analysis (Table 14). Hydropathic analyses of the data
indicated an energetic preference (the larger the positive number the more energetically
preferable) of the interaction of 20 and 24 at the ECD (917 and 627, respectively) allosteric site
over the TMD site (-390 and 251 , respectively, for TMD site characterized by Met253 and 129
and 273 , respectively, for TMD site characterized by Ser222). The Boltzmann-weighted score in
the score population for 20 and 24 at the ECD are 417 and 645, respectively, whereas Boltzmann
values for 20 and 24 at the TMD site characterized by Met253 are -639 and -386, respectively.
Boltzmann values for 20 and 24 at the TMD site characterized by Ser222 are -174 and -62,
respectively.
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Table 14. Summary of HINT and Boltzmann scores for the interactions of MD-354 (20) and its
N-methyl analog 24 at the two (i.e., the ECD and TMD) putative binding sites.

Site 3

NH
HN

NH 2

Site 6

ECD (Thr221)

TMD (Ser222)

TMD (Met253)

Hint

627 [-1.22]

273 [-0.53]

251 [-0.49]

Boltzmann Av.

417 [-0.81]

-62 [0.12]

-386 [0.75]

Cl

NH
H 3C

N

NH 2

Site 3

Site 6

ECD (Thr221)

TMD (Ser222)

TMD (Met253)

Hint

917 [-1.78 ]

129 [-0.25]

-390 [0.76]

Boltzmann Av.

645 [-1.25]

-174 [0.34]

-639 [1.24]

Cl

Different possible binding modes were suggested in our docking studies for 20 and 24 as
depicted in Figure 31. MD-354 (20) appears to utilize a binding mode at which N1 and N2 form
an ionic bond with Asp219 and possible hydrogen bonds with Ser206 and Thr221 (Figure 31A).
Furthermore, the same part of the guanidine moiety appeared to form a hydrogen bond with
Lys204, Ser206 and Asp219 amino-acid backbone oxygen atoms. The chloro group of 20
displayed Van der Waals interactions with the side chains of Pro202 and Lys204, and the
backbone of Gly203 (not shown) connecting these two amino acid residues from one side, and a
possible hydrogen bond with Thr223. In contrast, the N1-methyl analog 24 utilized the N2 and N3
atoms to form an ionic bond with Asp219 and possible hydrogen bonds with Ser206 and Thr221
(Figure 31B). In addition, the same part of the guanidine moiety appeared to form a hydrogen
bond with Asp219 and Ser206 amino-acid backbone oxygen atoms. The terminal N of Lys165
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seemed to form a possible cation-π interaction with the phenyl ring of 24. The chloro group of 24
displayed Van der Waals interactions with the side chains of Pro202 and Lys204, and the
backbone of Gly203 (not shown) connecting these two amino acid residues from one side, and a
possible hydrogen bond with the Thr223. The two distinct models (Figure 31) are consistent with
the functional data and in agreement with the common patterns of interactions of guanidinecontaining ligands in the PDB archive (Table 13).
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A

B

Figure 31. A and B represent the binding modes of MD-354 (20) and 24 in the ECD allosteric
site III of α7 nAChRs, respectively, and are depicted by the schematic representation in the
upper right corner (where D = Asp, aspartate). The lower right corner represents the
alignment of the orientation of both molecules.
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HINT contour maps, which contain hydrophobic/polar fields and acid/base fields, were
generated as another useful visualization of the above interactions of 20 and 24 with amino acids
at the binding site (ECD site III; Figure 32). The obtained data define the extent of polar and
hydrophobic intermolecular forces contained in the total scores obtained at each site (positive
values imply favorable interactions while negative values denote disfavorable interactions). Both
20 and 24 show more polar interactions at the ECD site compared to both TMD sites.

A

B

Location

Molecule

Total

Polar

Hydrophobic

Site III
(Thr221)

20

917

1267

-350

24

627

908

-281

Site VI
(Ser222)

20

129

202

-73

24

273

446

-173

Site VI
(Met253)

20

-390

224

-618

24

251

-27

278

Figure 32. HINT contour maps for the plausible binding site of MD-354 (20) and 24
showing a polar area (blue and red) and a hydrophobic area (green).
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D. Pharmacophore for Arylguanidines as α7 nAChR NAMs

In comprehensive reviews, Glennon, and Dukat164-166 discussed development of nAChR
pharmacophores from an historical perspective to the more recent α4β2 nAChR pharmacophores.
Briefly, the first attempt to determine the ligand features necessary for nicotinic cholinergic
activity was in 1952 when Hey defined two structural features, a quaternary amine separated by a
suitable distance from a partial positively-charged atom.164-166 In 1962, Barlow and Hamilton
estimated this distance to be 3.4 to 3.5 Å.164,165 A partial negatively-charged atom was also
reported by Holland and co-workers to be required in addition to the quaternary amine.164,165 In
1968, Kier reported an optimal distance of 4.85 Å between the quaternary amine and the partial
negatively-charged atom.164 A specific pharmacophore model for nAChR ligands was reported in
1970 by Beers and Reich.165-167 The model indicated that the specific binding of nicotinic
agonists to nAChRs is mediated by an electrostatic interaction between a positively-charged
nitrogen atom, and a hydrogen bond from an electronegative atom such as a carbonyl oxygen
atom or a nitrogen atom. Since that time, several publications about the pharmacophore showed
other details for the structural requirements of nAChR orthosteric ligands, such as a cationic
center, an electronegative atom capable of forming a hydrogen bond, and the center of a
lipophilic region (e.g., pyridine ring in (-)-nicotine (1)).168 Most of these studies were for
peripheral nAChRs or for neuronal α4β2 nAChRs.168,169 And, since then, other types of nAChRs
have been identified.
A pharmacophore model specifically for α7 nAChR orthosteric ligands, generally, fits the
classical three nAChR pharmacophoric elements (i.e., a cationic center, an electronegative atom
capable of forming a hydrogen bond, and a lipophilic center; Figure 33).170,171 However, some
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refinements of this model were reported in order to achieve subtype selectivity using α7 nAChRselective anabaseine analogs (e.g., GTS-21 (8)) and other α7 nAChR-selective N,Ndialkylpiperidine compounds.172 The refined model indicated a secondary (relatively small)
hydrophobic pocket that exists in the binding site of α7 nACh receptors closer to the charged
nitrogen pharmacophoric element (Figure 33).
On the other hand, there have been few previous attempts to determine a pharmacophore
model specifically for α7 nAChR allosteric ligands. For example, a small set of phthalazinone,
pyridazinone, and quinazoline compounds was identified through screening to possess high
potency as α7 nAChR PAMs.173 Compelling molecular modeling studies suggested that all three
classes of compounds display a common binding mode.173 Although some of the compounds
tested in this study were known to bind at the TMD allosteric site of α7 nAChRs (i.e., TMD
intrasubunit site (VI); Figure 30),171,173 no single compound has been reported to act at the
galantamine binding site (i.e., the ECD-lower exterior site (III); Figure 30). The authors
proposed a pharmacophore model consisting of a hydrogen bond donor, a hydrogen bond
acceptor, and three hydrophobic regions for the molecule in order to fit the proposed model
(Figure 34).173 To date, no NAM pharmacophore for α7 nAChR ligands has been reported.
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Figure 33. A pharmacophore model that confers selectivity for the α7 nAChR orthosteric
binding site. An analog of GTS-21 is embedded in the center of the model where the blue
lines indicate the classical α7 nAChR ligand pharmacophore, and the red line represents the
additional features for selective α7 nAChR ligands (adapted from Leonik et al.172 and
Lightfoot et al.174).
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Figure 34. A pharmacophore model for α7 nAChR PAMs. A quinazoline compound is
embedded in the center of the model where the blue lines indicate the pharmacophoric
elements at α7 nAChR allosteric sites (adapted from Capelli et al.173).
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Here, we attempted to define a pharmacophore for small-molecule arylguanidine NAMs at
α7 nAChRs using comparative molecular field analysis (CoMFA; an auxiliary set in SYBYL-X
2.1 used to assess 3D-QSAR). Our assumption here was that the compounds used in this study
might or might not interact in a similar manner at the site that we proposed, according to our
hydropathic analysis, to be most likely the ECD-lower exterior site (III) (Figure 30). CoMFA
provides an assessment of the relationship between electrostatic and steric interactions, and
biological activity, toward the determination of significant structural features within a group of
compounds. This was accomplished in two steps. First, we examined the entire set of
arylguanidines as a whole (n = 19). Next, we examined the two sets individually (i.e., the MD354 (20) or the aniline NH series, and the N-alkyl series, n = 7 and 12, respectively)
In our initial CoMFA run, we used the molecular conformation of each molecule as observed
in our docking solutions. Although CoMFA studies showed a high cross-validated r2 (q2) value
of 0.88 for the aniline NH series (n = 7) (i.e., 20-23, and 31-33; Table 7), it showed a low
predictive value of 0.02 and 0.01 (the predictability should be higher than 0.6 in order for the
model to be valid) for the whole arylguanidines set of compounds (n = 19) (i.e., 20-33, 37-39,
52, and 53; Table 7 and 12) and the N-alkyl series (n = 12) (i.e., 24-30, and 37; Table 7),
respectively. In a second run of CoMFA, all structures of the arylguanidines were manually
aligned (i.e., three non-linear points: the aromatic centroid, the cationic carbon and the meta
substituted carbon) to the most common conformations observed in our docking solutions. The
highest cross-validated r2 (q2) obtained by our CoMFA studies for the whole arylguanidine set of
compounds (n = 19) was 0.43, whereas the highest q2 value was -0.40 for the N-alkyl series (n =
12). The q2 value for the aniline NH series (n = 7) using manual alignment was similar to what
was obtained previously in the first CoMFA run (q2 = 0.88).
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In a third CoMFA run, we applied GASP175 (genetic algorithm similarity program; an
unbiased alignment algorithm implemented in SYBYL-X 2.1) to our compounds (i.e., 20-33, 3739, 52, and 53; Table 7 and 12) in order to perform the alignment step (Figure 35A). GASPguided alignments for all nineteen compounds were then used for our CoMFA studies. The
significance of each CoMFA model was indicated by a cross-validated r2 (q2) value that showed
a low predictive value of -0.36 for the nineteen arylguanidine compounds [seven compounds
(20-23, and 31-33; Table 7) from the MD-354 (20) series (i.e., all the currently investigated
analogs except the 3-CH3 analog due to uncertainty of its experimental results), eight compounds
from the N-methyl series (24-30, and 37; Table 7), and four compounds representing the chloro
and deschloro analogs of the N-ethyl and N-isopropyl compounds (38, 39, 52, and 53; Table
12)]. The results above indicated the possible lack of a common pharmacophore model for the
nineteen arylguanidine compounds due to the weak q2 values (CoMFA map is not shown).
GASP-guided alignments were also performed for the two individual sets of compounds. The
seven compounds (i.e., 20-23, and 31-33; Table 7) of the MD-354 (or NH) series were used for
GASP alignment (Figure 35B) and the results showed the possibility of a hydrogen bond being
formed (i.e., AS1) compared to the twelve compounds (i.e., 24-30, 37-39, 52, and 53; Table 7
and 12) representing the N-alkylated series (Figure 35C) where the AS1 hydrogen bond was
absent.
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Figure 35. Alignment of the molecules using GASP for the nineteen analogs (i.e., 2033, 37-39, 52, and 53) (A), the seven analogs representing the MD-354 series (i.e., 2023, and 31-33) (B), and the twelve analogs representing the N-alkylated series (i.e.,
24-30, 37-39, 52, and 53) (C) showing hydrogen bond Acceptor Sites (AS), and
HYdrophobic centers (HY) (yellow circles), and hydrogen bond Donor Atoms (DA).
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CoMFA studies showed a cross-validated r2 (q2) value for the seven compounds in the NH
series (i.e., 20-23, and 31-33; Table 7) of 0.78 (r2 = 0.98, SE = 0.036, number of components is
2) (Figure 36A). These results suggested that the model for the MD-354 (i.e., aniline NH series)
is dominated by a steric component, which explains about 91% of the variation in pIC50 at α7
nAChRs. The r2 of 0.98 for the model indicated a good correlation with pIC50 values.
The cross-validated r2 (q2) value for the twelve compounds (i.e., 24-30, 37-39, 52, and 53;
Table 7 and 12) representing the N-alkylated series was 0.44 (r2 = 0.95, SE = 0.07, number of
components is 4). This marginal value of q2 was improved to 0.60 when the number of
components was increased to 5 (r2 = 0.98, SE = 0.04) (Figure 36B). The model was dominated
by a steric component, which explains about 84% of the variation in pIC50 at α7 nAChRs. The r2
value of 0.98 for the model indicated a robust correlation with pIC50 values.
These results support our previous conclusion of possible different binding modes between
the two series (i.e., the MD-354 or NH series, and the N-alkylated series). That is, using an
unbiased GASP alignment, CoMFA failed to account for the action of the entire series of
nineteen compounds to behave as NAMs at α7 nAChRs. However, when examined separately,
the two series, that is, the MD-354 (or NH) series, and the aniline N-alkyl series, allowed the
identification of pharmacophore features. Overall, these studies support our other findings that
the NH and N-alkyl series bind in a different manner.
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B

A

Figure 36. CoMFA maps for the seven analogs (i.e., 20-23, and 31-33) representing the MD354 series (A) (n = 7, q2 = 0.78, r2 = 0.98; number of components = 2; 90.7% steric and 9.3%
electrostatic) and the twelve analogs (i.e., 24-30, 37-39, 52, and 53) representing the Nalkylated series (B) (n = 12, q2 = 0.60, r2 = 0.98; number of components = 5; 84.6% steric and
15.4% electrostatic). Green regions representing bulky substituents are favored, whereas the
yellow regions representing bulky substituents are disfavored. Blue regions represent
positively charged substituents are favored.

The N-alkyl arylguanidine series compounds appear to adopt a common binding mode, and
this differs from that of the MD-354 (i.e., NH) series in that the latter possesses five hydrogen
bonding sites, whereas the former only possesses four (see Figure 35B and 35C, respectively).
The model indicates the need for four hydrogen bond components and a hydrophobic region for
the molecule in order to fit the proposed pharmacophore model (Figure 37).
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Figure 37. A pharmacophore model for N-alkyl arylguanidine α7 nAChR NAMs. A
generalized N-alkyl arylguanidine is embedded in the center of the model where the
blue lines indicate the pharmacophoric requirements at α7 nAChR allosteric sites as
suggested by our pharmacophore study.

There are some shortcomings associated with our CoMFA studies (i.e., the relatively small
set of compounds and the narrow range of IC50 values). It should be kept in mind that all the
compounds were arylguanidines. Compounds such as the 3-chlorophenylethylamine (42), if it is
ever shown to be a NAM, can influence the pharmacophore. Nevertheless, the results suggest
new compounds that can be proposed, synthesized, and evaluated.176
Figure 37 describes the first pharmacophore model for N-alkyl arylguanidines as α7 nAChR
NAMs. It is rather interesting that the model lacks a hydrogen bond feature associated with the
anilinic nitrogen atom, a feature found in the MD-354 (or anilinic NH) model (see Figure 35B).
Because Dukat177 has previously proposed an anilinic NH as being important for binding of
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arylguanidines at 5-HT3 receptors, the lack of this feature might account for the greater α7
nAChR selectivity of the N-alkyl arylguanidines over the NH arylguanidines.

!
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V. Conclusions

A number of compounds based on MD-354 (20) and its N-methyl analog 24 were
synthesized and evaluated for their activity as inhibitors at α7 nACh receptors. MD-354 was
initially developed as a 5-HT3 receptor agonist earlier in our laboratory and has been found to be
the first example of a small-molecule NAM of α7 nAChRs. Our previous studies showed that the
incorporation of an N1-methyl substituent into arylguanidine led to compounds with enhanced
selectivity as NAMs of α7 nACh receptors. This indicated that the two actions can be divorced
and that removing structural features required for 5-HT3 receptor binding also resulted in
enhancement of α7 nACh receptor NAM potency. The N-methyl analog of MD-354 (i.e., 24)
showed 177-fold lower affinity than 20 for 5-HT3 receptors (i.e., 5-HT3 receptor Ki = 6,200 nM)
and higher potency at α7 nACh receptors (i.e., IC50 = 1.26 µM), examined using patch-clamp
technique on rat α7 nAChRs expressed in HEK cells, compared to MD-354 (20) (i.e., 5-HT3
receptor Ki = 35 nM; IC50 = 7.98 µM).
Previous molecular modeling studies9 indicated possible different binding modes between
MD-354 (20) and its N-methyl analog 24, which prompted us to investigate the structural
requirements for the action of arylguanidines at α7 nAChRs. One of the aims of this project was
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to study the SAR and determine the optimal structural features of arylguanidines for inhibiting
ACh responses at α7 nACh receptors. Figure 38 summarizes the three main structural regions
that were investigated for optimizing arylguanidine inhibitory action.

2

NH
R

1

3

N

NH 2

Cl

Figure 38. Representation of the three main structural components of arylguanidines
investigated in this study.

Two series of compounds were prepared, based on 20 and 24, to explore the aryl 3-position,
to test the effect of substituent size, lipophilic nature, and a different range of electronic effects
and to test a possible change in pharmacological profile of the new molecules. The structural
modifications included H, F, Cl, Br, I, CF3, OCH3, and CH3. Biological potencies of the MD-354
series and the N-methyl series of compounds, obtained from electrophysiological assays with
Xenopus laevis oocytes expressing human α7 nAChRs using a two-electrode voltage-clamp
assay, showed IC50 values ranging from 12 – 125 µM. Among those compounds, N-(3iodophenyl)-N-methylguanidine (28) was the most potent inhibitor of ACh responses at α7 nACh
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receptors. A poor correlation (r = 0.474; n = 8) of pIC50 values of the 20 series versus pIC50
values of the 24 series supported our docking results suggesting that the two series bind
differently. Hansch-type QSAR studies were conducted using several physicochemical properties
to determine the effect of similar modifications in the two series on NAM activity. Data for the
24 (i.e., N-CH3) series showed a significant correlation with the minimum width (Verloop B1) (r
= 0.927; n = 8) and lipophilic nature (π) (r = 0.912; n = 8) of the 3-position substituent.
However, a significant internal correlation exists between the two properties (r = 0.956; n = 8).
Consequently, additional analogs will be required to resolve this issue.176 Nevertheless, the effect
of the parallel structural modifications at α7 nAChRs and Hansch analyses indicate different
binding modes for the two series.
The Topliss operational scheme135 for the aliphatic side chain was used to optimize
pharmacological activities associated with the alkyl group at the anilinic nitrogen atom of the
arylguanidines at α7 nAChRs. According to the approach, replacement of the N-methyl group in
24 with an N-isopropyl group should increase its π effect.135 A total of four pairs of compounds
were initially examined at which the effect of the chloro group was also investigated through
deschloro compounds. Introduction of isopropyl groups was examined. The findings indicate that
the N1-iPr group (i.e., increased lipophilicity) appears to increase NAM potency, especially with
deschloro analogs where more pronounced effects are detected.
We also studied the role of the guanidine nitrogen atoms on the inhibitory effects of
arylguanidines at α7 nAChRs. The effect of alkylating one or more of the guanidine nitrogen
atoms, and the necessity of the presence of these nitrogen atoms for their NAM action, and/or
action as an α7 nAChR antagonist was investigated, because these structural changes are known
to be detrimental to 5-HT3 receptor binding. The results appear to support the concept that
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alkylation of the nitrogen atoms is well tolerated and that not all of the nitrogen atoms are
required for α7 nAChR antagonist action. However, more pharmacological studies are needed to
confirm this observation.
Molecular modeling studies were conducted to identify the potential binding site(s) as well as
the mode of interactions of arylguanidines at α7 nAChRs. Eight potential allosteric binding
cavities were initially identified, but only two of them, one at the extracellular domain (ECD)
and the other at the transmembrane domain (TMD), appeared to be reasonable binding sites for
our α7 nAChR allosteric modulators. Docking studies resulted in different binding modes for 20
and 24. HINT analyses were performed on the two binding sites and an energetic preference was
found for the interaction of 20 and 24 at the ECD allosteric site over the TMD site. These results
indicated that small-molecule arylguanidine NAMs (although the 20 and 24 series could bind
somewhat differently) might interact at the same binding site as PAMs at α7 nACh receptors.
A pharmacophore model for arylguanidine NAMs at α7 nACh receptors has not been
investigated previously. We initiated the first attempt to identify a pharmacophore model of
small-molecule arylguanidine NAMs of α7 nAChRs. Our pharmacophore studies showed a low
likelihood of a common pharmacophore model for all arylguanidine NAMs which supported the
possibility of different binding modes between the NH guanidines and the N-alkylated
guanidines. The first pharmacophore model of N-alkyl arylguanidines at α7 nAChRs was
proposed. Newly synthesized compounds will be subsequently used to evaluate the predictability
of the model, however, there might be a need for more compounds and a wider range of IC50
values in order to have better predictability.
Overall, three main regions in the arylguanidines were studied for their influence on
NAM action at α7 nAChRs. Multiple medicinal chemistry approaches were employed to
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rationally design novel α7 nAChR NAMs. We succeeded in improving the selectivity as well as
the potency of the parent compound MD-354 (20) toward α7 nAChRs. In addition, we have
constructed models of the ECD and the TMD of α7 nAChRs, energetically assessed binding at
the potential allosteric sites, and studied the plausible binding modes that might explain the
actions of our compounds. The study led to the 24 series of compounds and the N1-isopropyl
arylguanidine compounds that opened an investigation window to a number of compounds that
could guide us to promising novel α7 nAChR small-molecule NAMs.
Marijuana addiction, especially with the increasing legalization for medicinal and nonmedicinal use, increases the necessity to open a new approach for treatment of their abuse. For
medicinal chemists as well as other researchers in the drug discovery field, it is required to
investigate possible ways to fight diseases such as AD, depression and cognitive dysfunction.
Here, α7 nAChR-selective antagonists might represent a valuable pathway for promising
therapeutic strategy. Small-molecule NAMs (arylguanidines), because they offer an alternative to
orthosteric α7 nAChR antagonists, might represent a novel class of compounds with potential
therapeutic value.
!
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VI. Experimental

A. Synthesis

Melting points (mp) were taken in glass capillary tubes using a Thomas-Hoover melting
point apparatus and are uncorrected. Proton nuclear magnetic resonance (1H NMR) spectra were
obtained using a Bruker ARX 400 MHz spectrometer at which peak positions are given in parts
per million (δ) downfield from the internal standard tetramethylsilane (TMS), followed by the
splitting pattern (s = singlet, d = doublet, t = triplet, q = quartet, dd = doublet of doublets, m =
multiplet), coupling constant (Hz), and integration. Infrared spectra were obtained on a Thermo
Nicolet iS10 FT-IR. Purity of compounds was determined by elemental analysis performed by
Atlantic Microlab Inc. (Norcross, GA) for the indicated elements, and the obtained values are
within 0.4% of theoretical values. Reactions were monitored by thin-layer chromatography
(TLC) on silica gel GHLF plates (250 µm, 2.5 X 10 cm; Analtech Inc. Newark, DE), and Flash
chromatography was performed on a CombiFlash Companion/TS (Teledyne Isco Inc. Lincoln,
NE) using packed silica gel (Silica Gel 230-400 mesh) columns (RediSep Rf Normal-phase
Silica Flash Column, Teledyne Isco Inc., Lincoln, NE).

Electrospray ionization-mass

spectroscopy (ESI-MS) profiles were recorded using a Waters Acquity TQD (tandem
quadrupole) spectrometer in positive ion mode.
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N-Methyl-3-trifluoromethylaniline Nitrate (37). N-Methyl-3-trifluoromethylaniline nitrate
(37) was prepared according to a literature procedure for a similar compound.151 Cyanamide (0.7
g, 17.9 mmol) was added to a solution of N-methyl-3-trifluoromethylaniline hydrochloride (47)
(1.9 g, 8.9 mmol) in absolute EtOH (20 mL). The stirred reaction mixture was heated at reflux
for 24 h. Upon cooling, the reaction mixture was concentrated under reduced pressure to yield a
residue that was recrystallized from 1-butanol to give 4.8 g (21%) of the desired product as white
crystals: mp 247-249 °C; IR (diamond, cm-1): 3120 (NH), 3282 (NH2); 1H NMR (DMSO-d6) δ
3.29 (s, 3H, CH3), 7.72 (m, 2H, ArH), 7.79 (d, J = 7.68 Hz, 1H, ArH), 7.82 (s, 1H, ArH). Anal.
Calcd (C9H10F3N3·HCl) C, 42.62; H, 4.37; N, 16.57. Found: C, 42.66; H, 4.30; N, 16.52.
N-Isopropyl-N-phenylguanidine Nitrate (38). N-Isopropyl-N-phenylguanidine nitrate (38) was
prepared according to a literature procedure.152 An aqueous solution of cyanamide (50%; 1.5
mL) was added to a solution of N-isopropylaniline hydrochloride (48) (100 mg, 0.58 mmol) in
absolute EtOH (9 mL). The stirred reaction mixture was heated at reflux for 25 h, and then
cooled to 0 °C (freezer) for 20 h. The solvent was removed under reduced pressure, the resulting
oily residue was dissolved in H2O (1 mL) followed by addition of NH4NO3 (108 mg, 1.34
mmol). The solution was concentrated under reduced pressure and the residue was dissolved in
H2O (5 mL), washed with Et2O (3 x 20 mL), followed by evaporation of H2O under reduced
pressure. The resulting solid was recrystallized from H2O and, then, from absolute EtOH to give
30 mg (21%) of the desired product as white crystals: mp 164-165 °C; IR (Diamond) cm-1: 2159,
3172 (NH), 3319 (NH2); 1H NMR (DMSO-d6): δ 1.05 (d, J = 6.52 Hz, 6H, CH3), 4.4 (m, 1H,
CH), 7.3 (m, 2H, ArH), 7.6 (m, 3H, ArH). Anal. Calcd (C10H15N3·HNO3) C, 49.99; H, 6.71; N,
23.32. Found: C, 49.85; H, 6.64; N, 23.27.
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N-(3-Chlorophenyl)-N-isopropylguanidine

Hydrochloride

(39).

N-(3-Chlorophenyl)-N-

isopropylguanidine hydrochloride (39) was prepared using a literature procedure for a similar
compound.151 Cyanamide (1.02 g, 24.26 mmol) was added to a solution of 3-chloro-Nisopropylaniline (51) (2.50 g, 12.13 mmol) in absolute EtOH (30 mL). The reaction mixture was
allowed to stir at reflux for 24 h. The solution was concentrated under reduced pressure and
anhydrous Et2O (25 mL) was added. The white precipitate was collected by filtration and
recrystallized from i-PrOH to give 0.51 g (17%) of the desired product as white crystals: mp
272-274 °C; IR (diamond, cm-1): 3108 (NH), 3269 (NH2); 1H NMR (DMSO-d6) δ: 1.04 (d, J =
6.56 Hz, 6H, CH3), 4.36 (m, 1H, CH), 7.28 (td, J = 7.72, 1.62 Hz, 1H, ArH), 7.45 (t, J = 1.84 Hz,
1H, ArH), 7.58 (m, 2H, ArH). Anal. Calcd (C10H14ClN3·HCl) C, 48.40; H, 6.09; N, 16.93.
Found: C, 48.68; H, 6.11; N, 17.06.
N,N'-Di(3-trifluoromethylphenyl)urea (45). N,N'-Di(3-trifluoromethylphenyl)urea (45) was
accidently prepared using a patent procedure for the synthesis of carbamate compounds.178
Triethylamine was added to a solution of 3-trifluoromethylaniline (3.8 g, 23.6 mmol) in
anhydrous Et2O (10 mL). A solution of ethyl chloroformate (2.5 g, 23.6 mmol) in anhydrous
Et2O (5 mL) was added in a dropwise manner at 0 °C (ice-bath), and the stirred reaction mixture
was allowed to stir for 1 h at room temperature. The solid was collected by filtration and washed
with DCM to yield 0.7 g (18%) of 45 as a white crystals: mp 190-192 °C (179lit. mp 198 °C,
DMF/H2O); IR (diamond, cm-1): 1702 (CO), 3302 (NH); 1H NMR (DMSO-d6) δ 7.34 (d, J =
7.64 Hz, 2H, ArH), 7.53 (t, J = 7.80 Hz, 2H, ArH), 7.62 (d, J = 8.52 Hz, 2H, ArH), 8.01 (s, 2H,
ArH).
Ethyl N-[3-(trifluoromethyl)phenyl] carbamate (46). Ethyl N-[3-(trifluoromethyl)phenyl]
carbamate (46) was prepared according to a literature procedure.149 Sodium hydride 60% in
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mineral oil (0.5 g, 23.6 mmol) was washed with anhydrous toluene (2 × 5 mL) under an N2
atmosphere to remove the oil. The obtained solid was dissolved in anhydrous THF (10 mL) and a
solution of 3-trifluoromethylaniline (3.8 g, 23.6 mmol) in anhydrous THF (10 mL) was added. A
solution of ethyl chloroformate (2.5 g, 23.6 mmol) in anhydrous THF (5 mL) was added in a
dropwise manner at 0 °C (ice-bath), and the stirred reaction mixture was allowed to stir for 1.5 h
at room temperature. The mixture was filtered and the filtrate was concentrated under reduced
pressure and dried under high vacuum to yield 4.8 g (88%) of 46 as a yellow oil: IR (diamond,
cm-1): 1707 (CO), 3381 (NH); 1H NMR (DMSO-d6) δ 1.34 (t, J = 7.10 Hz, 3H, CH3), 2.71 (q, J
= 7.12 Hz, 2H, CH2), 7.36 (d, J = 7.76 Hz, 1H, ArH), 7.44 (t, J = 8.0 Hz, 1H, ArH), 7.57 (d, J =
8.36 Hz, 1H, ArH), 7.72 (s, 1H, ArH). The product was used without further characterization in
the preparation of 47.
N-Methyl-3-trifluoromethylaniline Hydrochloride (47). N-Methyl-3-trifluoromethylaniline
hydrochloride (47) was prepared according to a literature procedure.150 A solution of ethyl N-[3(trifluoromethyl)phenyl] carbamate (46) (5.0 g, 31.0 mmol) in anhydrous THF (15 mL) was
added in a dropwise manner to a stirred suspension of LiAlH4 (2.4 g, 64.3 mmol) in anhydrous
THF (15 mL) at 0 °C (ice-bath) under an N2 atmosphere. The reaction mixture was heated at
reflux overnight. Excess of LiAlH4 was decomposed by addition of H2O (2.5 mL), NaOH (2.5
mL, 15%), and H2O (7.5 mL), slowly and in a dropwise manner, and the mixture was allowed to
stir for 0.5 h. The reaction mixture was filtered and the collected solid was washed with hot THF
(10 mL). The filtrate was dried (MgSO4), solvent was removed under reduced pressure and dried
under high vacuum to yield 1.7 g of the free base of 47 as a yellow oil. The free base was
dissolved in Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The precipitate
was collected by filtration and recrystallized from a mixture of absolute EtOH/Et2O to give 1.9 g
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(44%) of the product as white crystals: mp 108-110 °C; IR (diamond, cm-1): 1453, 2638 (NH);
1

H NMR (DMSO-d6) δ 2.73 (s, 3H, CH3), 6.89 (m, 2H, ArH), 7.33 (m, 2H, ArH).

3-Chloro-N-isopropylaniline Hydrochloride (51). 3-Chloro-N-isopropylaniline hydrochloride
(51) was prepared according to a literature procedure.153 A mixture of 3-chloroaniline (49) (1.00
g, 7.83 mmol) and 2-bromopropane (50) (0.48 g, 3.92 mmol) was heated to 150 °C. Then, the
reaction mixture was allowed to cool to room temperature and washed with an aqueous solution
of NaOH (15%, 10 mL). The oily residue was shaken with an aqueous solution of ZnCl2 (10%,
10 mL). Excess ZnCl2 solution was decanted and the obtained residue was extracted with
petroleum ether (4×10 mL). The solvent was removed under reduced pressure and the residue
was purified by flash chromatography (silica gel; hexane/EtOAc; 9:1). The obtained oil was
dried under high vacuum for 6 h to yield 0.6 g (45%) of the free base of 51 as a yellow oil. The
free base was dissolved in Et2O and a saturated solution of HCl in anhydrous Et2O (50 mL) was
added. The precipitate was collected by filtration and recrystallized from a mixture of absolute
EtOH/Et2O to give 0.71 g of the desired product as white crystals: mp 238-239 °C; IR (diamond,
cm-1): 1594, 3044 (NH); 1H NMR (DMSO-d6) δ: 1.5 (d, J = 6.28 Hz, 6H, CH3), 3.52 (septet, J =
6.35 Hz, 1H, CH), 6.43 (d, J = 8.12 Hz, 1H, ArH), 6.54 (s, 1H, ArH), 6.59 (d, J = 7.84 Hz, 1H,
ArH), 7.0 (t, J = 8.02 Hz, 1H, ArH). The product was used without further characterization for
synthesis of compound 39.
N-Ethyl-N-phenylguanidine Hydrochloride (52). N-Ethyl-N-phenylguanidine hydrochloride
(52) was prepared according to a literature procedure.154 Cyanamide (299 mg, 7.10 mmol) was
added to a solution of N-ethylaniline hydrochloride (54) (800 mg, 5.09 mmol) in 1-pentanol (15
mL). The stirred reaction mixture was heated at reflux for 24 h. Upon cooling, the reaction
mixture was concentrated under reduced pressure to obtain an oily residue that was crystallized
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from a mixture of absolute EtOH/Et2O to give 209 mg (21%) of the desired product as off-white
crystals: mp 175-177 °C (154lit. mp 185 °C, EtOH/Et2O); IR (diamond, cm-1): 2977, 3189 (NH),
3303 (NH2); 1H NMR (DMSO-d6) δ: 1.10 (t, J = 7.12 Hz, 3H, CH3), 3.66 (q, J = 7.12, 7.14 Hz,
2H, CH2), 7.35 (d, J = 7.08 Hz, 2H, ArH), 7.47 (t, J = 7.34 Hz, 1H, ArH), 7.54 (t, J = 7.36 Hz,
2H, ArH).
N-(3-Chlorophenyl)-N-ethylguanidine

Hydrochloride

(53).

N-(3-Chlorophenyl)-N-

ethylguanidine hydrochloride (53) was prepared using a literature procedure for a similar
compound.151 Cyanamide (0.13 g, 3.12 mmol) was added to a solution of 3-chloro-N-ethylaniline
hydrochloride (55) (0.3 g, 1.56 mmol) in absolute EtOH (10 mL). The stirred reaction mixture
was heated at reflux for 24 h. Upon cooling, the reaction mixture was concentrated under
reduced pressure to obtain a residue that was recrystallized from a mixture of absolute
EtOH/Et2O to give 0.048 g (13%) of the desired product as white crystals: mp 186-189 °C; IR
(diamond, cm-1): 3077, 3187 (NH), 3274 (NH2); 1H NMR (DMSO-d6) δ: 1.07 (t, J = 7.16 Hz,
3H, CH3) 3.66 (q, J = 7.12, 7.16 Hz, 2H, CH2), 7.34 (m, 1H, ArH), 7.54 (m, 3H, ArH). Anal.
Calcd (C9H12ClN3·HCl) C, 46.17; H, 5.60; N, 17.95. Found: C, 45.93; H, 5.64; N, 17.72.
3-Chloro-N-ethylaniline Hydrochloride (55). 3-Chloro-N-ethylaniline hydrochloride (55) was
prepared according to a literature procedure.155 Acetaldehyde (1.5 mL, 27.0 mmol), 3chloroaniline (49) (3.4 g, 27.0 mmol), and pyridine-borane (1.9 mL, 22.5 mmol) were
sequentially added to a methanol solution (120 mL) containing powdered 4 Å molecular sieves
(2.4 g) under an N2 atmosphere. The stirred reaction mixture was heated at reflux for 24 h. Upon
cooling to room temperature, the mixture was filtered through a small bed of Celite (Hyflo
Super-Cel®) and the filtrate was collected. This filtrate was concentrated under reduced pressure
to give an oily residue. The residue was purified by flash chromatography (silica gel;
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hexane/EtOAc; 9:1) to obtain a solution that was concentrated under reduced pressure and dried
under vacuum for 14 h to yield 0.6 g of the free base of 55 as a yellow oil. The free base was
dissolved in Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The precipitate
was collected by filtration and recrystallized from a mixture of absolute EtOH/Et2O to give 0.7 g
(12%) of the product as white crystals: mp 144-146 °C; IR (diamond, cm-1): 1587, 2650 (NH);
1

H NMR (DMSO-d6) δ: 1.20 (t, J = 7.16, 7.20 Hz, 2H, CH2), 7.13 (d, J = 4.92 Hz, 2H, ArH),

7.24 (s, 1H, ArH), 7.37 (t, J = 4.16 Hz, 1H, ArH). The product was used without further
characterization for synthesis of compound 53.
N-(3-Cyanophenyl)-N-methylguanidine Nitrate (56). N-(3-Cyanophenyl)-N-methylguanidine
nitrate (56) was prepared using a literature procedure for a similar compound.151 Cyanamide
(0.25 g, 6.0 mmol) was added to a solution of 3-(methylamino)benzonitrile hydrochloride (59)
(0.5 g, 3.0 mmol) in absolute EtOH (15 mL). The stirred reaction mixture was heated at reflux
for 24 h. Upon cooling the reaction mixture, the solvent was evaporated under reduced pressure
and the obtained residue was dissolved in H2O (8 mL), followed by addition of NH4NO3 (0.29 g,
3.62 mmol). The solvent was evaporated under reduced pressure and the resultant semisolid was
recrystallized from EtOAc to give 0.13 g (19%) of the desired product as white crystals: mp 117119 °C; IR (diamond, cm-1): 2803, 3039 (NH), 3123 (NH2); 1H NMR (DMSO-d6) δ: 3.28 (s, 3H,
CH3), 7.74 (m, 2H, ArH), 7.89 (d, J = 7.48 Hz, 1H, ArH), 7.98 (s, 1H, ArH). Anal. Calcd
(C9H10N4·HNO3) C, 45.57; H, 4.67; N, 29.52. Found: C, 45.87; H, 4.68; N, 29.17; LRMS (ESI)
calculated for C9H11N4, [M + H]+, m/z 175.0905, found m/z 174.8022.
N-Cyclopentyl-N-phenylguanidine Hydrochloride (57). N-Cyclopentyl-N-phenylguanidine
hydrochloride (57) was prepared using a literature procedure for a similar compound.151
Cyanamide (0.64 g, 15.17 mmol) was added to a solution of N-cyclopentylaniline hydrochloride
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(62) (1.5 g, 7.58 mmol) in absolute EtOH (15 mL). The stirred reaction mixture was heated at
reflux for 24 h. Upon cooling, the solvent was evaporated under reduced pressure to obtain a
residue that was washed with cyclohexane and recrystallized from THF to give 0.15 g (9%) of
the desired product as white crystals: mp 209-211 °C; IR (diamond, cm-1): 2956, 3117 (NH),
3276 (NH2); 1H NMR (DMSO-d6) δ: 1.20 (m, 2H, CH2), 1.43 (m, 4H, CH2), 1.92 (m, 2H, CH2),
4.31 (m, 1H, CH), 7.28 (m, 2H, ArH), 7.53 (m, 3H, ArH). Anal. Calcd (C9H12ClN3·HCl·0.1
C6H12) C, 65.94; H, 9.06; N, 13.44. Found: C, 65.98; H, 9.13; N, 13.15.
N-(3-Chlorophenyl)-N-cyclopentylguanidine

Nitrate

(58).

N-(3-Chlorophenyl)-N-

cyclopentylguanidine nitrate (58) was prepared using a literature procedure for a similar
compound.151 Cyanamide (0.72 g, 17.23 mmol) was added to a solution of 3-chloro-Ncyclopentylaniline hydrochloride (63) (2.0 g, 8.61 mmol) in absolute EtOH (15 mL). The stirred
reaction mixture was heated at reflux for 24 h. The solution was concentrated under reduced
pressure and was dissolved in H2O (8 mL). The solution was washed with Et2O (3 x 20 mL),
followed by evaporation of H2O under reduced pressure. The resultant oily residue was dissolved
in H2O (8 mL), followed by addition of NH4NO3 (0.12 g, 1.44 mmol). The solvent was
evaporated under reduced pressure and the resultant semisolid was recrystallized from EtOH to
give 0.34 g (15%) of the desired product as white crystals: mp 225-227 °C; IR (diamond, cm-1):
2969, 3175 (NH), 3346 (NH2); 1H NMR (DMSO-d6) δ: 1.19 (m, 2H, CH2), 1.45 (m, 4H, CH2),
1.94 (m, 2H, CH2), 4.27 (m, 1H, CH), 7.29 (dd, J = 1.64, 7.52 Hz, 1H, ArH), 7.48 (s, 1H, ArH),
7.55 (m, 2H, ArH). Anal. Calcd (C12H16ClN3·HNO3) C, 47.93; H, 5.70; N, 18.63. Found: C,
48.06; H, 5.59; N, 18.61.
N-Cyclopentylaniline Hydrochloride (62). N-Cyclopentylaniline was synthesized according to
a patent procedure.180 Cyclopentanone (61) (3.8 mL, 43.0 mmol), acetic acid (1.2 mL, 21.5
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mmol), and sodium triacetoxyborohydride (9.1 g, 43.0 mmol) were added to a solution of aniline
(60) (2.0 mL, 21.5 mmol) in dichloromethane (15 mL) and the reaction mixture was allowed to
stir at room temperature for 1.5 h. The mixture was washed with saturated aqueous sodium
bicarbonate solution (3 × 25 mL) and the solvent was evaporated under reduced pressure, dried
under vacuum for 14 h to yield 4.0 g of the free base of 62 as yellow oil. The free base was
dissolved in anhydrous Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The
precipitate was collected by filtration and recrystallized from EtOAc to give 3.1 g (89%) of the
product as white crystals: mp 149-151 °C; IR (diamond, cm-1): 1584, 2631 (NH); 1H NMR
(DMSO-d6) δ: 1.55 (m, 2H, CH2), 1.77 (m, 4H, CH2), 1.85 (m, 2H, CH2), 3.88 (m, 1H, CH), 7.41
(m, 1H, ArH), 7.52 (m, 4H, ArH). The product was used without further characterization for
synthesis of compound 59.
3-Chloro-N-cyclopentylaniline

Hydrochloride

(63).

3-Chloro-N-cyclopentylaniline

hydrochloride (63) was synthesized according to a patent procedure for a similar compound.180
Cyclopentanone (61) (2.8 mL, 31.35 mmol), acetic acid (0.6 mL, 15.68 mmol), and sodium
triacetoxyborohydride (6.6 g, 31.35 mmol) were added to a solution of 3-chloroaniline (49) (1.6
mL, 15.68 mmol) in dichloromethane (15 mL) and the reaction mixture was allowed to stir at
room temperature for 1.5 h. The mixture was washed with saturated aqueous sodium bicarbonate
solution (3 × 25 mL) and the solvent was evaporated under reduced pressure and dried under
vacuum for 7 h to yield 2.7 g of the free base of 63 as yellow oil. The free base was dissolved in
Et2O and a saturated solution of HCl in Et2O (50 mL) was added. The precipitate was collected
by filtration and recrystallized from EtOAc to give 3.0 g (98%) of the product as white crystals:
mp 115-117 °C; IR (diamond, cm-1): 1589, 2628 (NH); 1H NMR (DMSO-d6) δ: 1.58 (m, 4H,
CH2), 1.72 (m, 2H, CH2), 1.88 (m, 2H, CH2), 3.78 (m, 1H, CH), 7.01 (m, 3H, ArH), 7.27 (m, 1H,
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ArH). The product was used without further characterization for synthesis of compound 58.

B. Electrophysiology
Xenopus oocytes: (studies were conducted by Shailesh Khatri, a graduate student in Dr. Schulte’s
Laboratory)
“Arylguanidine analogs were evaluated functionally using two-electrode voltage clamp of
human α7 nACh receptors expressed in Xenopus oocytes using previously published
procedures.181 Four independent recording stations with integral autosampling and data collection
were available for this study.
The chimeric DNAs (cDNA) for human α7 receptors were obtained from Dr. Jon
Lindstrom’s Laboratory (Department of Neuroscience, School of medicine, University of
Pennsylvania). cDNA was cloned into a pBud-CE4.1 (Invitrogen, CA) vector prior to RNA
synthesis.
Ovarian lobes were surgically removed from X. laevis frogs and washed twice in Ca2+ free
Barth’s buffer [82.5 mM NaCl/2.5mM KCl/1 mM MgCl2/5 mM HEPES, pH 7.4]. Lobes were
gently shaken with 1.5mg/ml collagenase (Sigma type II, Sigma–Aldrich) for 20-30 minutes at
room temperature. Stage IV oocytes were selected for microinjection. Synthetic cRNAs for wild
type human α7 were prepared using the mMESSAGE mMACHINETM High Yield Capped RNA
Transcription Kit (Ambion, TX). Each oocyte was injected with 50 nl cRNA at a concentration
of 300 ng/µl. Oocytes were incubated at 19 °C for 36-48 hours before electrophysiological
experiments. Electrical recordings were made using automated two-electrode voltage clamp at –
60 mV employing an OC-725C oocyte clamp amplifier (Warner Instruments, CT, US) coupled
to an online, computerized data acquisition system (pCLAMP, Molecular Devices, LLC, USA)
along with auto injection system (Gilson).
Recording and current electrodes were filled with 3 M KCl and had resistances of 1–4 MΩ.
Oocytes were held in a vertical flow chamber of 200-280µl volumes and perfused with ND-96
recording buffer (96 mM NaCl/2 mM KCl/1.8 mM CaCl2/1 mM MgCl2/5 mM HEPES, pH 7.4)
at a rate of 20 ml/min. Details of chamber and methodology employed for two electrode voltage
clamp recordings have been described earlier (Joshi et al., 2004). All agonists (Acetylcholine)
and antagonists (Analogs in test) were prepared in ND-96 buffer. Antagonists were co-applied
with 100µM acetylcholine (ACh) to record inhibition of ACh evoked currents by antagonist.
Dose–response curves obtained from electrophysiological data were fit using the equation I =
Imax/(1 + EC50/[A]n), where I is the current at a given agonist concentration, Imax is the
maximal current, EC50 is the agonist concentration that elicits a half-maximal current, and n is
the Hill coefficient. Ki were calculated using Cheng-Prusoff equation. All the analysis of the data
was done using GraphPad PRISM. Quantative data were expressed as mean ± S.E. Association
between the variables, where need, were tested by using paired students t test. All statistical
differences were deemed significant at the level of P<0.05.”182
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HEK 293 cells: (studies were conducted by Dr. Galya Abdrakhmanova)
“Stably transfected HEK 293 cells expressing rat α7 nAChRs were prepared as described
previously.183-185 All three cell lines were maintained at 37 °C with 5% CO2 in the incubator.
Growth medium for HEK 293 cells was minimum essential medium supplemented with 10%
fetal bovine serum, 100 U/ml penicillin, and 100 mg/ml streptomycin. The stably transfected cell
line was raised in selective growth medium containing 0.7 mg/ml of geneticin (Invitrogen Corp,
Carlsbad, CA). Growth medium for SH-EP1 cells was Dulbecco’s Modified Eagle’s medium
with high glucose supplemented with 10% heat inactivated horse serum, 5% fetal bovine serum,
100 U/ml penicillin, 100 mg/ml streptomycin, 8 mM L-glutamine, 1 mM sodium pyruvate, and
0.25 mg/ml amphotericin (all from Invitrogen Corp, Carlsbad, CA). This stably transfected cell
line was raised in selective medium containing 0.5 mg/ml zeocin (Invitrogen) and 0.4 mg/ml
hygromycin B (Roche Diagnostics Corp, Indianapolis, IN).”186
“Functional expression of nAChRs was evaluated in the whole-cell configuration of the
patch-clamp technique using an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA,
USA). The patch electrodes, pulled from borosilicate glass capillaries (Sutter Instrument
Company, Novato, CA, USA), had a resistance of 2.5–3.5 MΩ when filled with an internal
solution containing 110 mM Tris phosphate dibasic buffer, 28 mM Tris base, 11 mM EGTA, 2
mM MgCl2, 0.1 mM CaCl2, and 4 mM Mg-ATP (pH adjusted to 7.3 with Tris base).187,188 In
some cells, ~85% of electrode resistance was compensated electronically, so that the effective
series resistance in the whole-cell configuration was accepted when less than 20 MΩ. Stably
transfected HEK cells were studied for 2–3 days after plating the cells on 15-mm round plastic
cover slips (Thermanox, Nalge Nunc, Napierville, IL, USA). Generation of voltage-clamp
protocols and acquisition of the data were carried out using pCLAMP 9.0 software (Molecular
Devices). Sampling frequency was 5 kHz and current signals were filtered at 5 or 10 kHz before
digitization and storage. All experiments were performed at room temperature (22–25 °C).
Cells plated on cover slips were transferred to an experimental chamber mounted on the stage
of an inverted microscope (Olympus IX50, Olympus Corporation, Tokyo, Japan) and were
bathed in a solution containing 140 mM NaCl, 3 mM KCl, 2 mM MgCl2, 25 mM D-glucose, 10
mM HEPES, and 2 mM CaCl2 (pH adjusted to 7.4 with Tris base). The experimental chamber
was constantly perfused with control bathing solution (1–2 ml/min). The high-speed solution
exchange system, HSSE-2 (ALA Scientific Instruments, Westbury, NY, USA), was used to
deliver control and test solutions. Under optimal conditions, the delay in switching between
solutions was ~10 ms. Data presented herein were obtained through subtraction from the leak
current.”8
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C. MolecularModeling

The primary sequence of the human α7 nACh receptor was acquired from the Universal
Protein Resource (UniProt) (entry code: P36544; Homo sapiens). Multiple alignments of the hα7
nAChR sequence were performed with several orthologs by ClustalX 2.0137 using the following
UniProtKB accession codes: Q05941 (rat α7 nAChR; Rattus norvegicus), P22770 (chicken α7
nAChR; Gallus gallus). Homology models of the ECD and TMD of human α7 nAChRs were
generated using Modeller 9.12 (Version 9.12; University of California San Francisco, San
Francisco, CA) based on three templates: the X-ray crystal structure of a chimeric ECD of the α7
nACh receptor (PDB ID 3SQ9)70 that shares 64% sequence identity with the ECD of the human
α7 nACh receptor subunit, the NMR structure for the TMD of the α4 nAChR subunit (PDB ID
2LLY)74 that shares 49% sequence identity with the TMD of the human α7 nAChR subunit, and
the cryo-electron microscopic structure of the Torpedo marmorata nAChR (PDB ID 2BG9)21
that shares 53% sequence identity with the TMD of the human α7 nAChR subunit. All the
template structures were retrieved from the PDB Data Bank at http://www.rcsb.org. The
resulting models of each domain were evaluated based on the discrete optimized protein energy
(DOPE) and the molecular probability density function (Molpdf) scores and validated by the
docking of α7 nACh receptor modulators (i.e., galantamine for ECD, PNU-120596 and
ivermectin for TMD). A cavity-search study was conducted based on the Connolly surface
feature of SYBYL-X 2.1 (Tripos Inc. St. Louis, MO) and the blind docking approach within
AutoDock (Version 4.2; Scripps Research Institute, La Jolla, CA). The empirical data from two
α7 nACh receptor PAMs (i.e., ivermectin, PNU-120596) were used as a guiding tool in plausible
binding site exploration.
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Four low-energy rotamers of N-methyl mCPG were computationally prepared using SYBYLX 2.1. Molecular docking was conducted using the CHEMPLP scoring function within the
genetic algorithm docking program GOLD (Version 5.2; Cambridge Crystallographic Data
Centre, Cambridge, UK),175 and the docking solutions were analyzed (SYBYL-X 2.1). The
binding site was defined to include all atoms within 10 Å of the α-carbon atom of the key amino
acid residue for the candidate homology models. Based on the fitness scores and the binding
orientation of each ligand within the binding cavity, the best-docked solution was selected and
merged into the receptor. The initial models were energetically optimized using the Tripos Force
Field (Gasteiger–Hückel charges, distance-dependent dielectric constant = 4.0) to optimize the
interactions between ligand and receptor within the binding pocket, followed by PROCHECK
and ProTable analyses to validate the candidate models. These optimized model-ligand
complexes were then rescored with HINT (Hydropathic INTeractions) program;141 an empirical
scoring function based on the experimental free energy information derived from log Po/w (the
solvent partition coefficient for 1-octanol/water).
In the pharmacophore determination study, the compounds were aligned using GASP with
modifications in the default parameter. The population size (i.e., alignment solutions
conformations) was set to 125, the allele mutate weight (i.e., conformation diversity) to 96, and
the fitness increment (i.e., superimposition criteria) to 0.02. CoMFA calculations were conducted
using the QSAR module of SYBYL-X 2.1. The standard setting of 30 kcal/mol as energetic cutoff value was used. Regression analyses were performed using the SYBYL-X 2.1 tool of the
partial least square (PLS) algorithm with cross-validation (leave-one-out) and optimum number
of components.
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Appendix A

Concentration/response curves for compounds included in this study.
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Figure A1. Concentration/response curves for arylguanidines 21-23, 25-34, 37-39, 52,
and 53 (A-R) inhibition of peak currents elicited by 100 µM ACh at α7 nAChRs.
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Appendix B

Primary QSAR analyses for the N-methyl series compounds.

50

Figure B1. Plot of pIC50 values of the N-methyl analog series versus the electronic
character (σm) (r = 0.453, p = 0.260, n = 8).
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50

Figure B2. Plot of pIC50 values of the N-methyl analog series versus Verloop length (L)
(r = 0.763, p = 0.030, n = 8).

50

Figure B3. Plot of pIC50 values of the N-methyl analog series versus Verloop maximum
width (B5) (r = 0.448, p = 0.265, n = 8).
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50

Figure B4. Plot of pIC50 values of the N-methyl analog series versus the molar
refraction (MR) (r = 0.875, p = 0.021, n = 8).

!

50

Figure B5. Plot of pIC50 values of the N-methyl analog series versus the solvent
accessibility volume (Vol) (r = 0.882, p = 0.013, n = 8).
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Figure B6. Plot of pIC50 values of the N-methyl analog series versus the number of
valence electron (NVE) (r = 0.263, p = 0.528, n = 8).

50

Figure B7. Plot of pIC50 values of the N-methyl analog series versus the complete molar
refraction (CMR) (r = 0.893, p = 0.122, n = 8).
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Figure B8. Plot of pIC50 values of the N-methyl analog series versus the molar volume
(MV) (r = 0.540, p = 0.166, n = 8).
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Figure B9. Plot of pIC50 values of the N-methyl analog series versus Parachor values
(Pc) (r = 0.805, p = 0.023, n = 8).
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Figure B10. Plot of pIC50 values of the N-methyl analog series versus the polarizability
of the compounds (r = 0.890, p = 0.016, n = 8).
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